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ABSTRACT
There are few high-quality studies evaluating use of meshes in implant-based 
immediate breast reconstruction (IBR). This thesis analyzed current evidence 
of matrices and compared outcomes from the use of biological or synthetic 
meshes and traditional muscle-covered implants. The comparisons examined 
short- and long-term complications and corrections, predictors of 
complications, and patient satisfaction and quality of life (QOL). Manuscript I 
describes a systematic review and meta-analysis specifically assessing 
differences in outcomes between reconstructions with and without matrices. 
Manuscript II presents the results of reconstruction using a synthetic mesh 
[TIGR®; n = 49 patients (65 breasts)]. Manuscript III compares reconstruction 
outcomes using a biological mesh [Surgisis®; n = 71 (116 breasts)] with those 
from a traditional muscle-covered technique (n = 90; 132 breasts) regarding 
complications and health-related QOL. Manuscript IV compared outcomes 
from use of either a synthetic mesh (TIGR®; n = 49) or a biological mesh 
(Surgisis®; n = 53) regarding long-term patient satisfaction and health-related 
QOL. All patients were followed between 17 and 162 months.  
Meta-analysis revealed a possible increased risk of infection upon use of an 
acelullar dermal matrix (ADM), but not with synthetic meshes. The result must 
be interpreted with caution due to severe limitations in the included studies. 
Additionally, the results suggested that IBR with a synthetic mesh can be 
performed with a relatively low complication rate. The overall complication 
rate was higher using biological mesh as compared to muscle-covered 
implants; however, no significant difference was noted in implant loss rates 
between the groups. Predictors of complications were mainly patient-related, 
although high complication rates were associated with the use of tissue 
expanders, especially in patients with a history of irradiation. Furthermore, 
long-term patient satisfaction and QOL were similar when using a synthetic, 
biologic or no mesh, except for complications that affected patient satisfaction 
with the outcome. Our findings suggest that biological and synthetic meshes 
provide similar long-term quality of life. 
Keywords: immediate breast reconstruction, plastic surgery, acelullar dermal 
matrix, mesh, quality of life 
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SAMMANFATTNING PÅ SVENSKA 
Då kvinnobröst tas bort på grund av cancer eller ökad risk för cancer återskapas 
ofta bröstet med protes i samma operation, detta kallas för 
direktrekonstruktion. Det finns olika kirurgiska tekniker för att återskapa 
(rekonstruera) bröst. Under senare år har det blivit mycket vanligt att använda 
ett nät tillsammans med protesen. Trots att det nu är vanligt är det 
vetenskapliga stödet för nätanvändning svagt och studier är därför angelägna. 
Syftet med detta projekt är att undersöka om användningen av nät är säker och 
vilket nät patienterna tycker ger bäst resultat.  
Totalt har 210 kvinnor som genomgått direktrekonstruktion deltagit i 
studierna. Kvinnorna har rekonstruerats med antingen syntetisk nät, biologiskt 
nät eller traditionell muskeltäckt protes. De har följts under en period på mellan 
1,5 och 13,5 år, kontrollerats noga på mottagningen och svarat på enkäter om 
vad de tycker om bröstrekonstruktionen.  
I det första delprojektet visades att det vetenskapliga stödet för nät är mycket 
svagt och att det finns få bra studier på området. I det andra delprojektet visades 
att det förefaller säkert, i ett två årsperspektiv, att använda ett syntetiskt nät. I 
det tredje delprojektet visades att det kan vara mer komplikationer då 
biologiska nät används än vid traditionell muskeltäckt teknik. Riskfaktorer för 
komplikationer inkluderar rökning, övervikt och strålning. Patienterna som 
rekonstruerats med de två metoderna var lika nöjda med sina bröst enligt 
enkäterna. I delarbete fyra visades att patienter som opererats med biologiskt 
och syntetiskt nät förefaller vara lika nöjda med sina bröst på lång sikt.  
Tillsammans har dessa studier visat att ur komplikationssynpunkt förefaller det 
vara säkert att använda nät vid bröstrekonstruktion. Kvinnor som har 
direktrekonstruerats med olika tekniker förfaller lika nöjda och har liknande 
livskvalitet.  
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1 INTRODUCTION 
1.1 BREAST CANCER 
Breast cancer is the most common type of cancer among women in Sweden. 
In 2016, nearly 9000 cases were diagnosed, with one in 10 women at risk of 
developing breast cancer before the age of 75. Breast cancer is a multifactorial 
disease where heritage and environment play a part. Additionally, female 
hormones, both premenopausal and postmenopausal, represent important risk 
factors [1].   
Advances in diagnosis and treatment have improved patient prognosis, with 
the relative 10-year overall survival (OS) rate currently 86% [2]. As a 
consequence of better treatment and survival, the demand for either immediate 
or delayed breast reconstruction has increased, with those having an increased 
hereditary risk of breast cancer frequently requesting immediate breast 
reconstruction (IBR)  [1]. 
 
1.2 SUBCUTANEOUS AND NIPPLE-SPARING 
MASTECTOMY  
Recent advances in the pathophysiological understanding of breast cancer have 
radically changed surgical approaches from previous wide, clear surgical 
margins to the current no ink on tumour concept [3]. No ink on tumour is 
considered an oncologically safe surgical treatment for invasive breast cancer, 
where a 2-mm clear margin combined with whole-breast radiation therapy is 
considered safe for ductal cancer in situ (DCIS) [4]. This has led to less 
aggressive surgery and an increased proportion of breast-conserving therapy 
(BCT), often involving oncoplastic techniques, to obtain good aesthetic results. 
However, there still remain indications that might require a mastectomy [1]: 
 for oncologic reasons if the tumour is large or multicentric; 
 in cases where the patient previously received radiation 
therapy and BCT and further radiotherapy are not options; 
 in small breasts, where BCT would render an unacceptable 
aesthetic result; 
 in patients that wish to avoid postoperative radiation; and  
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 for prophylactic reasons in patients harbouring a cancer-
specific genetic mutation or at high risk of developing breast
cancer.
For patients needing a mastectomy, all women should be informed about the 
possibility of IBR [1]. 
1.2.1 THERAPEUTIC MASTECTOMY 
A therapeutic mastectomy can either be done as a simple (total) mastectomy, 
with excision of the gland and excessive skin, or as a skin-sparing 
(subcutaneous) mastectomy (SSM) combined with immediate reconstruction 
and with or without preservation of the nipple–areola complex (NAC) [i.e., 
nipple-sparing mastectomy (NSM)]. 
The first therapeutic mastectomy with implant-based reconstruction was 
performed in 1971 [5]. In cases of SSM, the operation consists of removing all 
breast tissue, often with an elliptical incision around the NAC, which is also 
removed. If the tumour is superficially located, the skin overlying it is often 
also removed, followed by dissection between the subcutaneous fat layer and 
the breast tissue. This layer is not always distinct in the breast, with previous 
results suggesting that some breast tissue will consistently be retained on the 
flaps, regardless surgical technique and especially if the flaps are >5-mm thick 
[6]. In a cadaver study by Goldman and Goldwyn [7], performance of a 
subcutaneous mastectomy through a submammary incision revealed residual 
glandular tissue in 42% of the cases (n = 12). 
It was previously feared that preserving the NAC would not be oncologically 
safe and could increase the risk of complications. A meta-analysis in 2010, 
comparing preservation of skin or not, indicated no difference in local 
recurrence (LR) rate between NSSM and NSM [8], although there were no 
randomized controlled studies included in that review. A more recent study 
from 2016 included >150 000 patients diagnosed with breast cancer between 
1988 and 2013 (median follow-up: 7.9 years) and showed that NSM was not 
associated with worse OS than SSM [hazard ratio (HR): 0.86; 95% confidence 
interval (CI): 0.52–1.42] [9]. However, among the limitations of the study were 
its inclusion of only patients with unilateral mastectomy and that lack of 
important data, including family history and genetic mutation status. In a 
review from 2015, 20 studies totalling 5594 patients evaluated outcomes of 
therapeutic NSM versus SSM and/or modified radical mastectomy, with 
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findings of no adverse oncologic outcomes of NSM in carefully selected 
women with early stage breast cancer [10]. Although the literature suggests 
that NSM is an oncologically safe procedure, indications and contraindications 
remain debatable. In a consensus report from 2018 [11], evaluation of the 
available literature and a panel discussion concluded that NSM is a safe 
procedure when performed by specialists selecting the right patients and 
techniques; however, contraindications were addressed regarding NAC 
preservation. The findings of report emphasized the need for standardization 
of NSM and IBR, as well as randomized trials and recommendations to register 
and evaluate patient-reported outcomes (PROs).     
The techniques used for NSM are similar to those described above, except for 
sparing the NAC and using different incisions. The type of mastectomy 
(conventional or skin- and/or nipple-sparing) depends upon breast shape and 
volume, tumour localization in the breast, the distance from the sternal notch 
to the NAC, and patient preference.  
 
1.2.2 PROPHYLACTIC MASTECTOMY 
According to Swedish guidelines [1], an investigation for suspected hereditary 
breast or ovarian cancer should be initiated in the following cases: 
 breast cancer diagnosed at <40-years old; 
 breast cancer diagnosed at <50-years old and with at least 
one first- or second-degree relative diagnosed with breast 
cancer;  
 breast cancer diagnosed at <60-years old and at least two 
first- or second-degree relatives diagnosed with breast 
cancer; 
 triple-negative breast cancer diagnosed at <60-years old; 
 male breast cancer, regardless of age at diagnosis; 
 ovarian or tubarian cancer or peritoneal carcinomatosis 
diagnosis, regardless of age; and   
 the presence of other hereditary syndromes associated 
with breast or ovarian cancer. 
In all patients where a prophylactic mastectomy might be relevant, the decision 
is made by the patient together with a multidisciplinary team (MDT) 
comprising a breast surgeon and a plastic surgeon and, in some cases, an 
oncologist/geneticist.  
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In an article from the Lancet in 1990 [12], data indicated that inherited breast 
cancer involved mutation(s) located on chromosome 17q21, with this work 
representing the starting point for current knowledge concerning hereditary 
breast cancer. There are a number of known mutations, with those in BReast 
CAncer susceptibility gene 1 (BRCA1; chromosome 17q) and BRCA2; 
chromosome 13q) the most common and associated with the highest risk of 
developing breast cancer. Patients with BRCA1 or BRCA2 mutations are 
diagnosed with breast cancer earlier (median: 45 years) as compared with the 
normal population, where the age at diagnosis is 63 years [2]. Other less 
common mutations, such as those in TP53, phosphatase and tensin homolog, 
partner and localizer of BRCA2 (PALB2), ataxia telangiectasia mutated gene, 
and checkpoint kinase 2 (CHEK2), are also associated with an increased risk 
of breast cancer. However, there are mutations that remain unknown in 
families with a history of developing breast cancer. Some of the most common 
mutations are listed in Table 1.  
 
Table 1. Common mutations related to breast cancer and their associated 
risk.  
Gene  Lifetime risk Ovarian 
cancer risk 
Risk for 
contralateral 
breast cancer 
Associated 
cancers 
BRCA1 High (50–80%) 30–60% Increased  
BRCA2 High (50–80%) 10–25% Increased Prostatic, 
pancreatic 
PALB2 Medium - high (14–
35%) 
Evidence 
lacking 
Unknown  
TP53 High No evident 
risk 
 Li-Fraumeni 
syndrome* 
CHEK2 Medium (20–25%) No increased 
risk 
 Elevated risk 
for colorectal 
cancer 
*Associated with a high risk of developing a number of malignancies, 
including paediatric cancer. 
In the absence of an identified mutation, the risk for developing breast cancer 
can be estimated using the BOADICEA model (Breast and Ovarian Analysis 
of Disease Incidence and Carrier Estimation Algorithm), a web-based program 
that calculates the risk for breast and ovarian cancer based on family history 
[13]. 
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In a review published in 2018 [14], surgical outcomes involving patients 
harbouring BRCA1/2, TP53, and PALB2 mutation revealed that: 
 BCT and mastectomy outcomes displayed equivalent OS 
in BRCA1/2 carriers at a 15-year follow-up, although 
after 15 years, the risk for LR was higher in the BCT 
group as compared with the mastectomy group (23.5% 
vs. 5.5%);  
 BCT outcomes in BRCA1/2 carriers versus non-carriers 
showed equivalent OS, although BRCA carriers had a 
significantly increased risk of LR and a relative risk of 
1.151 (median follow-up: ≥7 years); 
 no impaired OS was found in BRCA1/2 carriers due to 
radiotherapy; 
 one study showed that contralateral prophylactic 
mastectomy (CPM) reduced the risk of metachronous 
contralateral breast cancer but did not affect the OS, 
whereas another meta-analysis demonstrated a decrease 
in all-cause mortality; 
 in BRCA1/2 carriers without breast cancer, bilateral 
prophylactic mastectomy reduced the risk of breast 
cancer by >95%, with one meta-analysis showing 
reduced breast cancer-specific mortality and another 
showing no difference in all-cause mortality; and 
 although absolute risk of breast cancer in patients 
harboring a TP53 is unknown, mastectomy is 
recommended for both healthy carriers and those with 
breast cancer, whereas BCT is not recommended due to a 
higher susceptibility to radiation-induced DNA damage 
and risk for subsequent radiation-induced cancer 
(angiosarcoma). 
Similar findings were reported in a review by Ludwig et al. [15] evaluating 
data examining the effect of prophylactic oophorectomy and concluding that 
both risk-reducing mastectomy and oophorectomy reduced the risk of both 
breast and ovarian cancers. Moreover, improvements in ovarian cancer related 
and all-cause mortality were reported in association with oophorectomy 
(moderate quality data) but not in mastectomy (very low quality data) [15]. 
A large prospective study involving 3722 patients with information concerning 
oophorectomy status and followed either until breast cancer diagnosis, 
prophylactic mastectomy, or death [16] revealed no significant difference in 
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annual incidence of breast cancer in all patients, regardless of having 
undergone prophylactic oophorectomy (yes: 1.9%; no: 1.6%). After 
stratification according to BRCA1 or BRCA2 mutation, annual incidence 
changed to 1.7% and 1.5%, respectively, and after stratifying for age at 
diagnosis, no association was found between oophorectomy and BRCA1 
mutation in patients aged <50 years, although a significant reduction in breast 
cancer was observed in patients harbouring a BRCA2 mutation and aged <50-
years but not in patients aged >50 years (p = 0.007). Despite no differences in 
overall effect of prophylactic oophorectomy on breast cancer, their findings 
based on ovarian cancer onset were that prophylactic oophorectomy should be 
recommended at age 35 for BRCA1 carriers and age 40 for BRCA2 carriers. 
In a Swedish national survey from 2011 and including 223 women undergoing 
bilateral prophylactic mastectomy at eight different hospitals between 1995 
and 2005 [17], no primary breast cancer was found during a median follow-up 
of 6.6 years. All patients had a history of high risk of breast cancer without 
prior breast malignancy, and risk calculations  performed using BOADICEA 
[13] on 204 patients revealed that ~12 incidences of breast cancer were 
expected in the absence of bilateral prophylactic mastectomy. 
The alternative to surgery in patients without cancer is screening for early 
detection of a malignancy. Swedish guidelines recommend that women 
harbouring a BRCA1/2 mutation begin screening starting at age 25 and 
continuing until age ~74 and receiving mammogram and magnetic resonance 
tomography (MRT) examinations from ages 25 to ~55 [1]. For patients with a 
moderately increased risk (>20%), onset of screening starts at 5 years before 
the first onset of breast cancer according to family history or no later than age 
40. 
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1.3 IMMEDIATE IMPLANTE BASED BREAST 
RECONSTRUCTION (IBR) 
1.3.1 INDICATIONS AND CONTRAINDICATIONS OF 
IBR  
Swedish guidelines require that all patients receiving a planned mastectomy be 
informed that immediate reconstruction is an option, and that the decision 
regarding the procedure will be made at an MDT conference [1]. 
Absolute contraindications for IBR include locally advanced breast cancer, 
inflammatory breast cancer, and mental instability or an inability to understand 
the impact of the reconstruction, risks, and complications. Relative 
contraindications include obesity (body mass index (BMI) > 30), active 
smoking, and/or a comorbidity that could affect healing or risks that might 
extend surgery time. Additionally, irradiation is associated with higher risks 
for complications, especially for implant-based reconstructions, and should be 
avoided [1, 18]. 
 
1.3.2 QUALITY OF LIFE (QOL) ASSOCIATED WITH 
IBR 
From an historical point of view, evaluations of breast reconstruction have 
mainly focused on surgical outcomes, with less attention given to patient 
opinion on the result. Data from the literature are inconsistent about the effect 
of an immediate reconstruction as compared with a simple mastectomy without 
reconstruction on QOL. A review by Lee et al. [19] found that seven of 11 
studies reported no significant difference in QOL between those reconstructed 
immediately and those receiving simple mastectomy only, with three studies 
reporting better QOL, and one reporting worse QOL. The majority of the 
studies used generic instruments; however, the five studies using specific 
instruments for breast cancer (Breast-Q and EORTC QLQ BR-23) showed no 
difference or worse outcomes in QOL when an IBR was performed. 
Regarding body image, nine of 16 studies found no significant differences 
between IBR and mastectomy alone, and seven studies reported better body 
image following IBR, with only one study reporting use of a breast cancer-
specific instrument [19]. 
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Regarding sexuality and sexual function, seven of 12 studies found no 
difference between women undergoing reconstruction and women undergoing 
mastectomy without reconstruction. Three studies reported improved 
outcomes, and two reported poorer outcomes in sexual function following IBR. 
Only two of the studies reported using instruments specific for breast cancer 
[19]. 
In contrast to the review from 2009 [19], a previous study comparing the QOL 
of 92 patients receiving immediate reconstruction as compared with 45 patients 
receiving mastectomy alone found that  women with successful reconstruction 
reported significant improvements in the appearance of their chest/breasts (p = 
0.003) and better psychosocial (p = 0.008) and sexual (p = 0.007) feelings as 
compared with patients receiving mastectomy alone according to Breast-Q 
results[20]. Additionally, the reconstructed patients reported improved 
physical function (p = 0.012) and experienced fewer limitations and pain (p = 
0.007). RAND-36 measurements of the same patients showed significant 
differences in physical functioning and pain, with the reconstructed patients 
scoring better. The study concluded that the patients benefitted from breast 
reconstruction following mastectomy, although the study was very limited and 
had scientific flaws. Moreover, outcomes from those with complications, 
including radiotherapy, were not presented. 
PROs can vary in the event of serious complications. A study from 2015 
reported the results of a 10- and 20-year follow-up of 621 patients with a 
history of breast cancer who underwent CPM [21]. Of these, 403 patients 
underwent IBR, with most of the patients reporting stable long-term 
satisfaction (79%); however, patients with unplanned re-operations were 
significantly less satisfied and less likely to choose CPM again. Moreover, the 
group undergoing CPM without immediate reconstruction reported higher 
satisfaction (90%; p = 0.0001) relative to those receiving immediate 
reconstruction; however, both groups reported that they would definitely 
choose CPM again (80% in the reconstruction group vs. 91% in the group 
without reconstruction) [21]. 
A recent study investigating the accuracy of patient predictions of future well-
being after IBR found that both patients with IBR and those receiving a 
mastectomy without reconstruction misjudged their own outcomes at 12-
months post-surgery [22]. Patients undergoing a mastectomy without 
reconstruction underestimated their future well-being according to all Breast-
Q domains, and those undergoing reconstruction generally overestimated the 
future outcomes associated with satisfaction with their breasts-unclothed, 
sexual attractiveness-clothed, and sexual attractiveness-unclothed.  
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1.3.3 IMPLANTS AND EXPANDERS IN IBR 
The first silicone implant was invented by Dr. Tomas Cronin and initially 
tested on a dog, followed by use in a female patient [5, 23]. The production of 
breast implants has since become more strictly regulated [24, 25]. 
ONE- OR TWO-STAGE IBR? 
An implant-based IBR can be performed as a one- or two-stage procedure. A 
one-stage reconstruction involves insertion of a permanent implant or 
permanent tissue expander (TE) in connection with the mastectomy. A two-
stage procedure involves insertion of a temporary TE at the mastectomy site, 
followed by its replacement with a permanent implant after expansion and a 
specific time period.  
The choice between performing a direct-to-implant (DTI) IBR or a two-stage 
operation with a tissue expander (TE) and subsequent insertion of a permanent 
implant depends upon a number of factors. The advantages of a DTI include 
fewer operations, especially if an NSM is performed, and shorter 
reconstruction time, although there might be risks of additional complications 
as compared with a two-stage reconstruction. 
A meta-analysis from 2016 analysing outcomes between one- and two-stage 
implant-based reconstructions reported a statistically significant (p = 0.02) 
increase in the risk for implant loss and a significantly higher risk for total 
complications (p = 0.03) in the one-stage group as compared with the two-
stage group[26]. Additionally, comparison of NSM with non-NSM indicated a 
significantly higher risk (p = 0.01) for both implant loss and total complications 
in the one-stage group; however, comparison of one-stage NSM with two-stage 
NSM showed no significant differences for any complication. There was no 
information concerning the use of meshes. 
Only three studies have reported aesthetic outcomes based on evaluations 
performed using different panels, with no significant differences found 
between one- and two-stage reconstructions. However, the one-stage group 
had lower total costs, despite higher costs associated with complications. The 
study concluded that one-stage reconstruction is comparable with two-stage 
reconstruction in patients with NSM, despite the higher cost of complications, 
but that controlled studies are required to draw solid conclusions [26]. 
A review from 2015 of 10 retrospective cohort studies, two prospective cohort 
studies, and one prospective randomized trial including >5000 patients showed 
no significant differences in risk for hematoma, seroma, infection, or capsular 
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contracture between one- and two-stage reconstruction [27]. However, the 
risks of flap necrosis [odds ratio (OR): 1.43; CI: 1.09–1.86) and re-operation 
due to complications (OR: 1.25; CI: 1.02–1.53) were higher in the DTI group. 
Additionally, 11 studies reported implant-loss rates exhibiting a significantly 
increased risk in the DTI group (OR: 1.87). The authors noted study 
limitations, including bias in selecting DTI or TE, and the fact that subgroup 
analysis could not be performed regarding the use of acellular dermal matrix 
(ADM), irradiation, and chemotherapy due to lack of data. Moreover, they 
stressed the need for data concerning PROs and QOL [27]. 
In a recent prospective multicentre study of 99 patients who underwent DTI 
and 1328 patients operated on with TE and later exchanged to a permanent 
implant[28], no significant differences were found in complications. PROs 
assessed with a panel of questionnaires, including use of the Breast-Q with 
baseline data from the time of surgery and follow-up after 2 years revealed no 
significant differences in satisfaction with breasts, psychosocial well-being, 
physical well-being, except for sexual well-being, were DTI scored better [28]. 
DTI was the standard procedure for early implant-based breast reconstruction; 
however, the use of expanders increased along with increased demand for IBR. 
The introduction of ADM resulted in another increase in DTI use due to reports 
that ADM might improve results and decrease complications [29]. A 
multicentre study (11 centres and 1427 patients) compared 2-year complication 
rates and PROs for DTI compared with TE, with results indicating that there 
were more complications in the DTI group (32.3% vs. 26.2%), although the 
differences were not statistically significant. PROs measured preoperatively 
and after 2 years showed that patients in the DTI group scored significantly 
better for sexual well-being, but otherwise no differences were found. 
Reconstructive failures were excluded from the analysis [28]. 
Traditional muscle-covered IBR 
Tissue that remains following a mastectomy is often very thin and vulnerable 
due to decreased blood supply. Moreover, the space under the flaps is wide and 
increases the risk of implant movement, especially laterally, and rippling of the 
overlaying skin. To address this issue, additional tissue allowing coverage with 
a layer of muscle is needed. Traditional surgical techniques aimed to achieve 
complete coverage over the implant by opening the major pectoral muscle in 
the direction of the muscle fibre, thereby creating a pocket comprising the 
major pectoral muscle and the lateral serratus muscle (Figure 1) [30].  
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Figure 1. Complete muscle coverage (implant pocket represented in blue color). 
Copyright: Wolters Kluwer: 2016, Cordeiro et al., Two-stage Implant-based 
Breast Reconstruction: An Evolution of the Conceptual and Technical Approach 
over a Two-Decade Period, Plastic and Reconstructive Surgery, 138(1), p 1-11. 
Https://journals.lww.com/plasreconsurg/pages/default.aspx. 
 
Disadvantages of these procedures include the difficulty of DTI due to the lack 
of expansion, especially in larger breasts. Even when a TE is used, the 
expansion of the lower pole can result in a flattened appearance and a less 
successful aesthetic result. Currently, the preferred technique involves dual-
plane dissection, where the major pectoral muscle is released from the inferior 
attachment and medially at the sternum, and a pocket is created between the 
thoracic wall and the serratus muscle in order to prevent lateral movement of 
the implant (Figure 2). The main advantage of this technique is improved 
lower-pole expansion, which provides a more naturally shaped breast, whereas 
the main disadvantage is the risk of pectoral-muscle retraction, which would 
result in less coverage in the lower pole. In both cases, either an implant or TE 
is introduced in the newly created pocket.  
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Figure 2. Partial muscle coverage, dual plane. Copyright: Wolters Kluwer: 2006 
Tebbetsl., Dual Plane Breast Augmentation: Optimizing Implant-Soft-Tissue 
Relationships in a wide Range of Breast Types, Plastic and Reconstructive 
Surgery, 118(7), p 81-98. 
Https://journals.lww.com/plasreconsurg/pages/default.aspx. 
 
Alternative lower-pole coverage: dermal sling and meshes 
These techniques sometimes involve problems with implant positioning and a 
lack of tissue in the lower pole in the case of dual-plane muscle coverage, with 
accompanying increased risks of implant exposure and a sub-optimally defined 
submammary fold. The introduction of ADMs and synthetic meshes and their 
use in breast reconstruction offered a potential resolution to many of the 
shortcomings associated with muscle coverage. The surgical technique is 
similar to that for the dual-plane procedure; however, to achieve coverage of 
the lower pole of the breast, the matrix or mesh is sutured to the submammary 
fold and to the lower part of the pectoral muscle and laterally to the chest wall, 
without raising the serratus muscle. The result is a more complete coverage of 
the implant and the creation of an ´internal bra´. 
In the case of a larger and ptotic breast, the inferior portion of the skin 
envelope, with or without preservation of the NAC, can be de-epithelialized 
and used to cover the lower pole of the breast (Figure 3-4). The skin is 
subsequently sutured to the lower part of the pectoral muscle, as described 
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above. Using patient-derived tissue has the advantage of no extra cost and 
minimized risk for foreign body reaction, which can be an issue with biological 
and synthetic meshes. Additionally, this method allows NAC preservation in 
large and ptotic breasts, where disadvantages include smaller breast size in 
most cases [30, 31]. 
 
 
 
 
 
 
 
Figure 3. Dermal sling, with preserving of the NAC, incision. With permission 
from Journal of Plastic, Reconstruction & Aesthetic Surgery: Lewin et al., 
Immediate breast reconstruction with a wise pattern mastectomy and NAC-
sparing McKissock vertical pedicle dermal flap, 2018, 71(10), p 1432-1439  
 
 
 
 
 
 
 
 
Figure 4. Dermal sling, with preserving of the NAC, flap raised. With permission 
from Journal of Plastic, Reconstruction & Aesthetic Surgery: Lewin et al., 
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Immediate breast reconstruction with a wise pattern mastectomy and NAC-
sparing McKissock vertical pedicle dermal flap, 2018, 71(10), p 1432-1439  
1.3.4 MESHES USED IN IBR 
The first study citing the use of allograft dermis in aesthetic breast surgery to 
reduce rippling in 34 patients with breast implants was published[32]. Apart 
from one patient suffering an infection and another developing a capsular 
contraction, no complications were noted, and patients reported a high degree 
of satisfaction [32]. 
The first use of mesh in an IBR was presented by Breuing and Warren [33]. 
Bilateral mastectomy and immediate reconstruction were performed in 10 
patients and using an allograft, Alloderm® (LifeCell Corporation, Woodlands, 
TX, USA) to cover the lower/lateral part of the breast. The allograft eliminated 
the need for a TE and provided an option for single-stage reconstruction with 
an implant, with one complication involving suture-line ischemia during the 
follow-up period (6–12 months) reported. 
Numerous studies have since been published reporting varying results and a 
number of mesh-specific advantages [34], as follows: 
 a decreased or eliminated need for expanders; 
 reduced post-operative pain; 
 decreased operation time; 
 increased initial-fill volumes of the expander; 
 fewer expansions; 
 precise control over the lateral and inframammary folds; 
 increased ability to use more of the mastectomy skin 
flaps; 
 faster completion of the reconstruction; 
 improved lower-pole expansion; 
 decreased incidence of capsular contraction; 
 fewer capsular modifications at second-stage surgery; 
and 
 improved aesthetic outcome. 
In a review by Nguyen et al. [34], the proposed advantages were addressed, 
and consistent support for decreased incidence of capsular contraction was 
found, although following limited long-term follow-up. All other proposed 
advantages were considered mostly anecdotal [34]. 
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BIOLOGICAL MESHES: ADM 
Biological meshes include those derived from human dermal tissue [i.e., ADM; 
e.g., Alloderm®, Allomax®, FlexHD®, and Dermacell®) and those derived 
from non-human sources, such as xenografts from pig skin, pig bowel 
submucosa, or pericardium from veal (e.g., Strattice®, Surgisis®, and 
Veritas®). 
ADM from human tissue is not approved for use in Sweden but represents the 
most used mesh in the United States. In nearly 90 000 annual IBRs performed 
in the United States, an ADM (mostly Alloderm®) was used in the majority of 
cases [35]. All biologic meshes are processed using different techniques in 
order to remove donor cells and potential pathogens while retaining other 
structures. The meshes can either be sterile or aseptic, with differences in mesh 
sourcing and processing evidently unimportant [35]. In randomized trials 
performed by Mendenhall et al. [36, 37] comparing Alloderm® and 
Dermamatrix®, the biological ADMs that had been processed differently 
showed no significant differences in complications [36, 37]. There are few 
studies comparing human- and xenograft-derived ADM [35]. 
SYNTHETIC MESHES 
The use of synthetic meshes has become more common in recent years due to 
the high costs of and unclear evidence associated with the use of biologic 
meshes [34]. Synthetic meshes can be either absorbable (TIGR® Matrix, 
SERI® scaffold, and Vicryl®) or permanent (TiLOOP® bra, ULTRAPRO®, 
Surgimesh-PET®, and Gore® DualMesh). Meyer Ganz et al. [38] compared 
IBR between a group with a complete submuscular pocket (46 breasts) and a 
group with a partial submuscular pocket in combination with a Vicryl® mesh 
(115 breasts), findings no significant difference in early complications at a 90-
day follow-up (4.4% vs. 11.6%, respectively). Moreover, at a 5-year follow-
up, early and late complications were similar. with 41.3% in the total 
submuscular group and 33.9% in the Vicryl® mesh group. However, there 
were significantly fewer surgical revisions necessary in the mesh group (8.9%) 
as compared with 21.7% in the non-mesh group (p = 0.05). 
Dieterich et al. [39] retrospectively compared IBR with and without permanent 
TiLOOP®  in order to evaluate differences in QOL with a validated instrument 
Breast-Q [40]. The results indicated no significant differences in complications 
across the entire study group (90 patients), with an overall complication rate 
of 21.1%. Comparison of QOL outcomes showed no differences in Breast-Q 
results between the groups.  
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BIOLOGIC VERSUS SYNTHETIC MESHES 
There are relatively few studies comparing outcomes associated with the use 
of biological and synthetic meshes. In one prospective randomized trial, 
Gschwantler-Kaulich et al. [41] compared use of an ADM (Protexa®) with that 
of TiLOOP®, with an initial report of higher incidence of  severe 
complications, including implant loss (p < 0.0001), in the Protexa® group. Due 
to the small sample size (n = 48), this statement was later corrected to a non-
significant but increased risk for implant loss in the Protexa® group (p = 0 
.068)[42]. This study was subsequently criticized by Potter et al. [43] for their 
lack of a primary end point, definition of complications, and use of validated 
specific QOL instruments. 
 
1.3.5 COMPLICATIONS IN IMPLANT-BASED IBR 
EARLY COMPLICATIONS 
Complications following IBR are evaluated at both short- and long-term 
periods. Most authors define early complications as events within 30 days, 
although these are often loosely defined in many articles, thereby making it 
difficult to compare incidences between different studies. Early complications 
are often divided into minor complications, such as seroma, hematoma, minor 
necrosis or infections, and others not needing any surgery or hospitalization 
but merely local treatment or medication, whereas major complications are 
mostly defined as events that either have serious consequences involving 
failure of the reconstruction or major medical events that require 
hospitalization with surgery and/or medication. 
A study by Arver et al. [17] of 223 patients receiving bilateral IBR with either 
autologous reconstruction, DTI, or TE/implant (TE/I) at eight centres reported 
that 52% of patients experienced one or more complications, the most common 
of which was partial skin necrosis in 29.9%, followed by wound infection 
(17.0%), blood loss requiring transfusion (9.0%; 67% in the autologous group 
and 9% in the implant groups), hematoma (8.1%), seroma (7.6%), and wound 
rupture (3.6%). Serious non-breast-related complications occurred in 3% of 
patients, with implant loss of 10%. Similar complication rates were reported in 
a study of 269 women, where 64% indicated one or more complications within 
1 year of surgery [44], and the majority of complications occurring within 1 
month after surgery. Neither of these articles addressed the eventual impact of 
irradiation or mesh use on the development of a complication. 
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In a study evaluating the effect of radiation on IBR, Eriksson et al.[18] showed 
that radiation administered before reconstruction resulted in a reconstruction-
failure rate of 25%, whereas patients receiving radiation postoperatively 
displayed a reconstruction-failure rate of 15% relative to a 6% rate in non-
irradiated patients. 
In a review by Basta et al. [27], 13 studies with a total of 5216 patients and 
comparing complications between DTI with TE/I reconstructions revealed 
higher risks of flap necrosis  (OR: 1.43; p = 0.0.1), implant loss (OR: 1.87; p 
= 0.04), and re-operation due to complication in the DTI group (OR: 1.25; p = 
0.04) (Tables 2 and 3). 
 
Table 2. Studies included in the meta-analysis. * 
 
 
 
 
 
 
*Copyright: Wolters Kluwer: 2018, Basta et al., A systematic Review and 
Head-to Head Meta-analysis of outcomes following Direct-to-Implant versus 
Conventional Two-stage Implant Reconstruction, Plastic and Reconstructive 
Surgery, 136(6), p 1139. 
Https://journals.lww.com/plasreconsurg/pages/default.aspx. 
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Table 3. Comparison of complications observed between DTI and TE 
reconstruction according to a meta-analysis. * 
 
 
 
 
*Copyright: Wolters Kluwer: 2018, Basta et al., A systematic Review and 
Head-to Head Meta-analysis of outcomes following Direct-to-Implant versus 
Conventional Two-stage Implant Reconstruction, Plastic and Reconstructive 
Surgery, 136(6), p 1139. 
Https://journals.lww.com/plasreconsurg/pages/default.aspx 
 
Because complications often are reported as occurring with 30-days post-
surgery, there might be a risk that total complication rates are underestimated. 
In a study of 903 IBRs, Hansen et al. [45] showed that the overall complication 
rates at day 30 at 5.9%, which increased to 18.9% at the 1-year follow-up. 
Additionally, implant-loss rate also increased from 2.3% to 13.2%. Moreover, 
univariate analysis revealed that patients reporting a complication at 1-year 
post-surgery were significantly older, experienced additional comorbidities, 
and had a higher BMI as compared with patients reporting no complications. 
 
LATE COMPLICATIONS 
Some complications appear later after primary surgery, with capsular 
contraction an example of one that can develop years after the initial breast 
reconstruction. Capsular contraction is a complication reportedly caused by 
local excessive formation of collagen due to a foreign body reaction [46]. The 
exact mechanism remains unclear; however, one theory is that it is caused by 
a complex combination of bacterial contamination in the implant pocket, which 
stimulates inflammation and leads fibroblast proliferation and collagen 
deposition and contracture [47, 48], thereby resulting in a firm and sometimes 
painful breast. The grade of capsular contraction is traditionally classified 
using the Baker classification system [49], which was originally intended for 
augmentation mammoplasty and represents a subjective evaluation of breast 
firmness by a physician. Spear and Baker [50] modified this system to allow a 
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more accurate description in the context of breast reconstruction, with the 
modified system including Grades I through IV: 
 Grade I, a normal breast;  
 Grade II, a mild contraction with no symptoms;  
 Grade III, a moderate capsular contracture, where the 
implant can be palpated easily and might be visible or 
distorted; and 
 Grade IV, severe firmness with significant distortion and 
pain/tenderness. 
The surface of the implant plays a major role in elevated risk of developing 
capsular contraction. A meta-analysis [51] reported an OR of 0.19 (CI: 0.07–
0.052) in favour of textured implants as compared with smooth implants. 
Implant surfaces have been altered over time, and recent 
nanotechnology/microtechnology has improved implant interactions with 
surrounding tissue in order to reduce the risk of capsular contraction, although 
no clinical long-term follow-up studies have been performed [47]. 
The incidence of capsular contraction varies in the literature from a low 
percentage to ~30% [52], with this representing the most common overall 
indication for re-operation among patients with breast implants. Handel et al. 
[53] reported that the cumulative risk for developing capsular contraction 
increases by the time the implant is in place according to Kaplan–Meier 
analysis [data derived from a mean follow-up of 37.4 months (range: 0–280)]. 
In contrast to Barnsley et al. [51] they [53]reported no differences observed in 
contracture incidence between smooth and textured implants, but noted a 
decreased incidence with polyurethane foam-covered implants.  
 
BREAST-IMPLANT-ASSOCIATED CANCER 
In 2006, the results of a long-term epidemiologic study with an average follow-
up time of 18 years involving women with cosmetic breast implants showed 
no increased risk of breast or other cancers [54]. In 1995, a case report of three 
patients with cutaneous T-cell lymphoma and breast implants indicated 
possible associations between breast implants in young females and cancer 
onset, although the causality was unknown [55]. Another study not long after 
the case report identified T cell lymphoma in the proximity of an implant [56]. 
Jong et al. [57] described patients with breast implants and diagnosed with 
anaplastic large T-cell lymphoma (ALCL) in the breast and suggested a 
possible association with the implants. A subsequent report described 56 cases 
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diagnosed in New Zeeland and Australia between 2007 and 2018 [58]. The 
evidence for an association between ALCL and breast implants is now well 
established, and the World Health Organization classified breast-implant-
associated ALCL (BIA-ALCL) as a new entity in 2016[59]. BIA-ALCL onset 
usually presents as a seroma formation between the implant and the 
surrounding fibrous capsule, with the median interval from primary surgery to 
onset of the lymphoma ~10 years [59]. The exact incidence in Sweden is not 
known but is generally considered low (i.e., ~10 cases have been diagnosed 
since 2016). Due to the low incidence of BIA-ALCL, its diagnosis and 
treatment have varied among different centres worldwide. The National 
Comprehensive Cancer Network published guidelines for the diagnosis and 
management of BIA-ALCL in a consensus meeting in 2017 [60]. 
 
RISK FACTORS FOR COMPLICATIONS 
The causes of IBR-related complications are multifactorial and include those 
that are patient-, surgery, and treatment-related [61]. 
Patient-related risk factors 
Several patient-related factors, such as smoking, BMI, and advanced age, 
increase the risk for IBR-related complications. Song et al. [62] measured 
cerebral blood flow by quantitative MRT in 15 healthy men (age <45 year), 
revealing a significant decrease in blood flow after smoking [7.3% (p = 
0.024)]. In two studies of >10 000 patients, the ORs for implant loss or skin 
necrosis in active smokers was 4.0 and 3.55, respectively (Table 4) [63, 64]. 
Additionally, Lardi et al. [65] showed that the risk for implant loss or skin 
necrosis/infection doubled in patients presenting a BMI >30 (Table 4), and 
Eriksson et al. [18] reported an increased risk for implant loss in patients 
presenting a BMI >25 (HR: 2.01; p = 0.002). Furthermore, Fischer et al. [63] 
and Jimenez-Puente et al. [66] found patients aged >50 were at an increased 
risk for implant loss/reconstructive failure (Table 4).  
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Table 4. Reports of patient-related risk factors associated with IBR.  
 
 
Surgery related risk factors 
IBR-related complications are often related to thin mastectomy flaps and 
impaired blood circulation. Surgery related risk factors for complications have 
been identified and are presented below. 
Surgeon experience  
Studies show that surgeon experience can affect the risk for complications. 
Eriksson et al. [18] performed multivariate analysis, revealing that the risk for 
reconstruction failure increased for reconstructive surgeons with <5 years of 
experience (HR: 3.62; CI: 1.61–8.12; p = 0.002). Additionally, Gfrerer et al. 
[64] analysed the importance of surgeons, revealing a significant variation in 
the risk for skin necrosis among surgical oncologists, with ORs varying 
between 0.69 and 2.98. Reconstructive teams were analysed according to 
number of performed procedures (ranges: <150, 150–300, and >300), with 
multivariate analysis showing an increased rate of infections in the group with 
the least experience (OR: 2.48; p < 0.05).  
 
Risk 
factor: 
Fischer et al. 
(n = 9305)[63] 
  
Jiménez-Puente 
et al. (n = 112) 
[66] 
  
Lardi et al. 
(n = 149)[65]  
  
Gfrerer et al. 
(n = 3142)[64] 
  
Outcome Implant loss Reconstructive 
failure 
Any complication Skin 
necrosis 
Infection 
Age (y) >55; (OR: 2.0; CI: 
1.3–3.2; p = 0.004)  
>50; (OR: 3.02; 
CI: 1.19–7.67; p 
= 0.02) 
NR OR=1.01          
(p=.0556)        
OR=1.02 
(p=0.092) 
BMI 
(k/m²) 
>30 
OR: 1.7; CI: 1.1–
2.7; p = 0.03 
NR OR: 2.16; CI: 
1.07–4.33; p = 
0.0308 
OR=2.12          
(p=<0.01)      
OR=1.7 
(p<0.05) 
Active 
smoker 
OR: 4.0; CI: 2.5–
6.4; p = 0.001 
NR Mastectomy 
weight >600 g or 
BMI >30  kg/m2 
OR=3.55          
(p<0.01)         
OR=0.63 
(p=0.380 
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IBR versus delayed breast reconstruction (DBR) 
There are few randomized trials comparing complications between IBR and 
DBR. A previous study [67] of >17 000 patients and comparing wound 
complications following IBR and DBR (with IBR defined as surgery within 7 
days of mastectomy and DBR as a mastectomy without IBR within >7 days of 
surgery) indicated that for IBR, the incidence of surgical-site infection was 
significantly higher (8.9%) as compared with 3.3% in the DBR group. By 
contrast, surgical-site infections were similar between IBR and DBR in an 
autologous reconstruction group (9.8% vs. 13.9%). Additionally, surgical-site 
infections and non-infectious wound complications were higher in secondary 
implant reconstructions receiving adjuvant radiotherapy relative to autologous 
reconstruction, where no increased rates were observed. These results 
suggested that some high-risk patients might benefit from DBR or autologous 
reconstruction to reduce the risk of serious complications [67]. 
One-stage (DTI) versus two-stage (TE/I) breast reconstruction 
Srinivasa et al. [28] compared DTI and TE/I groups, showing no significant 
differences in the rates of complications, which occurred in the range of 26.2% 
to 32.3% of the time while reconstructive failure occurred from 7.4% to 8.1% 
of the time. Additionally, ADM was more frequently used in the DTI group 
(92.9%) as compared with the TE/I group (51.7%), and radiation was more 
common in the TE/I group. Regression analysis showed significant 
complications associated with BMI, age, smoking status, laterality, lymph 
node management, and radiation. 
Incision for breast reconstruction 
Incision and implant type can affect the risk of developing complications. A 
systematic review comparing one-stage reconstruction (DTI) with two-stage 
reconstruction (TE) and using a Wise pattern incision showed an increased risk 
for overall complications in the DTI group as compared with the TE group 
(30.3% vs. 20.3%) [68].  
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Figure 5. Examples of incision used in immediate breast reconstruction. Wise 
pattern with and without saving NAC, E and J. 
Reprinted by permission from Springer Nature: Current Surgery Reports, Nipple-
Sparing Mastectomy: To Spare or Not to Spare, Akiko et al., 2016   
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Treatment-related risk factors 
Preoperative and postoperative radiotherapy 
Preoperative or postoperative radiation is associated with a higher risk of 
complications, although the literature shows large heterogeneity in the size of 
the increased risk. A study from Sweden of 725 patients operated on at four 
hospitals evaluated irradiation and PRO measures, finding a reconstructive-
failure rate of 6% in non-irradiated patients (NoRT) as compared with 25% for 
those receiving irradiation before mastectomy (BMRT) and 15% in patients 
receiving irradiation postoperatively (PMRT)[18]. The median follow-up was 
43 months, and estimation of the 5-year failure rate revealed a 10.4% risk in 
the NoRT group, a 28.2% risk in the BMRT group, and a 25.2% risk in the 
PMRT group, with no report of the eventual impact of mesh use[18]. Similar 
findings were reported from a single-centre study of 210 patients (265 
breasts)[69], where PMRT showed an increased rate of expander infection as 
compared with NoRT (20% vs. 2.6%; p = 0.001) and expander removal (26% 
vs. 8.3%; p = 0.007), with the overall failure rates for both expander use and 
later exchange to a permanent implant of 26.1% (BMRT), 21.2% (PMRT), and 
6.2% (NoRT). 
In a large database study analysing data from 4781 patients who underwent 
mastectomy combined with radiotherapy and breast reconstruction (IBR or 
DBR), the overall complication rate associated with IBR was 45.3% as 
compared with 30.8% with autologous reconstruction, with reconstruction-
failure rates of 29.4% and 4.3%, respectively[70]. Among the study limitations 
were that it only included patients using insurance and lacked information 
concerning race/ethnicity, BMI, smoking status, prior surgery, and surgery 
preference. Moreover, the study did not include information about the use of 
meshes; however, the authors concluded that their analyses offered insight into 
the morbidity of irradiated patients undergoing varies types of breast 
reconstruction. 
A recent prospective multicentre study of 622 irradiated and 1625 non-
irradiated patients showed that at a 2-year follow-up, 38.9% of IBR patients 
had experienced at least one complication in the irradiated group as compared 
with 25.6% of those undergoing autologous reconstruction and irradiation, 
whereas 28.3% of the non-irradiated group experienced a complication[71]. 
Additionally, Laporta et al. [72] performed a multivariate analysis based on 
288 patients receiving a mixture of autologous and implant-based NSM, with 
BMRT patients showing an increased risk of complications (OR: 10.14; CI: 
3.99–27.01; p < 0.001). 
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1.3.6 AUTOLOGOUS IBR 
Autologous breast reconstruction was first reported in 1895, with Vincenz 
Czerny describing transfer of a lumbar lipoma to a breast as a substitute after 
a lumpectomy [23, 73].  
THE LATISSIMUS DORSI FLAP 
In 1896, the first breast reconstruction using the latissimus dorsi myocutaneous 
flap was described by the Italian surgeon Iginio Tansini [74]. This method did 
not gain interest until Olivari ‘rediscovered’ the flap and deemed it safe and 
suitable for treating irradiation damage or addressing recurrence following 
mastectomy [75]. Subsequent development of the method resulted in its 
frequent use as both a pedicle flap for breast reconstruction, as well as other 
types of reconstructions in the area, and as a free flap for other reconstructive 
procedures. 
ABDOMINAL FLAPS 
From the early 1900s to the late 1970s, different tubed flaps were tested for 
breast reconstruction. However, flaps from the abdomen gained wider interest 
after Mathes and Bostwick [76] first described use of the rectus abdominis 
myocutaneous flap for reconstruction of the abdominal wall, with its later use 
for breast reconstruction. Additionally, Holmström [77] described a novel 
technique involving use of a rectus abdominis myocutaneous free flap with 
microvascular anastomosis for breast reconstruction. This method was derived 
from observations of abdominoplasty procedures, which confirmed that 
elevation of an abdominal flap on isolated vessels did not compromise tissue 
viability. Hartrampf et al. [78] later described a technique using a transverse 
rectus abdominis myocutaneous (TRAM) flap in breast reconstruction. The 
work of Holmström [77] offered a foundation for later work by Taylor [79] 
describing muscle-saving technique, where the flap comprised the lower part 
of the rectus abdominis muscle and preserved the periumbilical rectus 
abdominis perforators. Later, the deep inferior epigastric perforator (DIEP) 
flap was invented by Allen and Treece [80] in an attempt to preserve the rectus 
abdominis muscle, with this technique currently used following subsequent 
modifications. 
OTHER AUTOLOGOUS RECONSTRUCTION METHODS 
Other methods in addition to those using the latissimus dorsi and TRAM/DIEP 
flaps have been developed. The first free gluteal myocutaneous flap for use in 
breast reconstruction was described by Fujino [81], with other flap variations 
subsequently developed [23, 82]. 
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2 AIMS 
The aims of this thesis were as follows: 
 Analyze differences in cancer recurrence, oncologic 
treatment, health-related quality of life, complications, 
and aesthetic outcomes between the use of a matrix or no 
matrix (I); 
 
 Examine short-term complications (<30 days) and 
predictors of complications following breast 
reconstruction using a TIGR® Matrix Surgical Mesh 
combined with a tissue expander/implant (TE/I) or a 
direct-to-implant (DTI) (II);  
 
 Compare short- and long-term (>90 days) complications 
and predictors of complications, as well as long-term 
patient quality of life and satisfaction, following 
immediate TE/I-based breast reconstruction using a 
Surgisis® matrix and a traditional muscle-cover 
technique (III); and  
 
 Compare patient quality of life and satisfaction following 
immediate breast reconstruction (IBR) using a biological 
mesh (Surgisis®) or a synthetic mesh (TIGR®) (IV). 
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3 PATIENTS AND METHODS 
3.1 STUDY DESIGN 
Study I was a systematic review and meta-analysis, study II was a case-series 
study, study III was a case-control study, and study IV was a cross-sectional 
study between two cohorts from studies II and III. 
 
3.2  EVALUATION METHODS AND DATA 
COLLECTION 
3.2.1 SYSTEMATIC REVIEW AND META-ANALYSIS 
(I) 
A systematic review is a research technique that qualitatively summarises the 
results of multiple studies in order to generate the highest grade of evidence, 
whereas a meta-analysis quantitatively synthesizes the studies using statistical 
methods [83]. Inclusion criteria for our study were defined according to PICO 
(Patient, Intervention, Comparison, and Outcome) and designed in accordance 
with the aims of the study.  
Patients: 
 One- or two-stage IBR in women with hereditary risk of 
developing breast cancer or diagnosed with breast cancer 
and either having received or not received radiation 
treatment. 
Intervention: 
 Breast reconstruction with a biologic mesh or a synthetic 
mesh. 
Control: 
 Breast reconstruction without a mesh. 
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Outcome: 
 HrQoL 
 Breast cancer recurrence and associated mortality 
 Aesthetic outcome 
 Complications (e.g., implant loss or infections) 
 Capsular contraction 
 Delayed neo-adjuvant therapy due to complications 
 
For the meta-analysis, we included all randomised and non-randomised 
controlled trials and either case series with >200 patients reconstructed using 
a biologic mesh, AlloDerm® or those with >20 patients reconstructed using 
any other ADMs or matrices/meshes.  
For study I, systematic searches were performed in May 2016 of PubMed, 
Embase, the Cochrane Library, the Centre for Reviews and Dissemination 
database, and the websites of the Swedish Agency for Health Technology 
Assessment and Assessment of Social Services (SBU) and the Norwegian 
Knowledge Centre for the Health Services. Additionally, the lists of references 
in relevant manuscripts were scrutinised for relevant studies. Searches were 
conducted using a controlled vocabulary and words taken from titles and 
abstracts. The search was limited to studies in English, Swedish, Danish, and 
Norwegian and to articles published from 2005 to 2016. Literature searches, 
study selection, and abstract assessment were performed separately by two 
different researchers, and any disagreements were resolved in consensus. All 
authors read the selected articles independently, and a consensus meeting 
determined which articles should be included in the assessment. 
The included studies were critically appraised using a checklist for the 
assessment of cohort studies [84] modified from that used by the SBU by the 
Centre for Health Technology Assessment at Sahlgrenska University Hospital. 
The appraisal addressed directness (external validity), risk of bias (internal 
validity), and precision using a three-level scale. Data were extracted by at 
least two authors per outcome.  
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The certainty of evidence across studies was assessed by all authors and rated 
separately for all outcomes according to the GRADE system (Grading 
Recommendation Assessment Development and Evaluation) [85] as high 
, moderate , low  or very low  quality: 
 High: “Further research is highly unlikely to change our 
confidence in the estimate of the effect.” 
 Moderate: “Further research is likely to have an important 
impact on our confidence in the estimate of the effect and 
might change the estimate.” 
 Low: “Further research is very likely to have an important 
impact on our confidence in the estimate of the effect and 
likely to change the estimate.” 
 Very low: “Any estimate of the effect is very uncertain.” 
 
3.2.2 CLINICAL EVALUATION (II–IV) 
For studies II through IV, patients were clinically evaluated at 1-week and 3- 
and 12-months post-operatively and thereafter based on need. We used a 
clinical case report form to ensure standardization of patient evaluation for all 
complications. 
The registered demographic variables included age, preoperative BMI (the 
ratio of the body mass in kilograms and the square of the height in meters), and 
smoking status. The registered clinical details included comorbidities, 
laterality, reason for mastectomy, type of mastectomy, specimen weight (using 
scales with an accuracy of 0.01 kg), implant type and size, perioperative 
inflation volume in millilitres, receipt of preoperative or postoperative 
radiotherapy, and complications. 
Determinations of which complications to register were based on previous 
studies [86] and divided into major complications, including implant loss (e.g., 
implant exposure, mesh exposure, implant loss, and infection leading to 
implant loss), mastectomy skin flap epidermolysis/necrosis requiring revision, 
NAC epidermolysis/necrosis requiring revision, thrombosis, and embolism, 
and minor complications, including seroma requiring aspiration, hematoma 
requiring re-operation, type IV delayed hypersensitivity reactions (i.e., “red 
breast”), epidermolysis not requiring revision, minimal wound 
rupture/necrosis not requiring revision, and infections not leading to implant 
loss. 
Håkan Hallberg 
 
31 
Infection was graded from 1 to 4, as previously described [87], where grade 1 
indicates wound exudate, grade 2 indicates redness, swelling, heat, and 
exudate, grade 3 indicates redness, swelling, heat, and purulent drainage or 
induration, and grade 4 indicates fever and/or sepsis. All re-operations and 
corrections were registered during long-term follow-up. 
 
3.2.3 QUALITY OF LIFE-QUESTIONNAIRES 
Historically, outcome reports on breast surgery focused on surgical techniques, 
complications, and aesthetic outcomes and often used non-validated methods, 
with less emphasis on patient reported outcomes, PROs. In recent decades, 
HrQoL has become an important measurement used to evaluate the results of 
different surgical procedures [88]. HrQol can be measured based on different 
dimensions, including general health and physical, mental, and psychosocial 
well-being. The instruments used to evaluate these parameters can be either 
generic, such as the SF-36 survey instrument [89] and the hospital anxiety and 
depression scale (HADS) [90], or disease-specific, such as the Breast-Q [40].  
All included questionnaires were delivered by post to the patients and controls 
along with an explanatory letter and a return envelope. A reminder was 
delivered after 2 weeks to those who had not returned the questionnaire.  
BREAST-Q (II–IV) 
Patient satisfaction and well-being were measured using the Swedish version 
of the postoperative reconstruction module of BREAST-Q [40, 91]. BREAST-
Q was developed to measure QOL in breast patients and has been validated 
[40, 91], with translation to Swedish performed according to guidelines for the 
linguistic validation of PRO instruments [92]. Only domains relevant to the 
aims of the studies were analysed, including the following (Figure 6).  
 QOL domains: 1) psychosocial well-being; 2) sexual 
well-being; and 3a) physical well-being (chest and upper 
body)  
 Satisfaction domains: 1) satisfaction with breasts, and 5) 
satisfaction with outcome.  
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Figure 6. Breast-Q domains and sub-domains.  
 Copyright: Wolters Kluwer: 2009, Pusic et al., A systematic Review and Head-to 
Head Meta-analysis of outcomes following Direct-to-Implant versus Conventional 
Two-stage Implant Reconstruction, Plastic and Reconstructive Surgery, 124(2), p 
345-353. Https://journals.lww.com/plasreconsurg/pages/default.aspx. 
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EUROQOL FIVE-DIMENSION QUESTIONNAIRE WITH THREE 
LEVELS (EQ-5D-3L) (IV) 
The EQ-5D-3L comprises a five-dimension, three-level scale that measures 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 
A global score, where 1 indicates “perfect health” and 0 “death”, is calculated 
from the answers. A visual analogue scale (VAS) was included for the patient 
to evaluated his/her current health state from 0 (“worst imaginable”) to 100 
(“best imaginable”). The EQ-5D-3L was initially developed for economic and 
clinical evaluation of health care, but has since been used to evaluate breast 
reconstruction [93] and validated for the Swedish language [94] (Figure 7). 
Figure 7. EQ-5D domains. ( Niclas Löfgren) 
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HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS) 
The HADS instrument measures anxiety experienced during the previous week 
and comprises 14 questions (seven covering anxiety and seven covering 
depression). Each question is scored from ³QHYHUQRLQWHQVLW\´WR³HYHU\
GD\YHU\LQWHQVH´, and for each scale, a total score is calculated. A total score 
RI7 is judged as no depression or anxiety, a score between 8 and 9 suggests 
that depression or anxiety might be present, and a score >9 indicates that the 
presence of depression or anxiety is plausible. The instrument has been used 
to evaluate breast reconstruction [95, 96] and translated to Swedish [97] Figure 
8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The HADS questions. Amonn, K; Stortecky, S, Quality of life in high- 
risk patients: comparison of transcatheter aortic valve implantation with surgical 
aortic valve replacement, Eur J Cardiothorac Surg. 2012;43(1):34-42. By 
permission of Oxford University Press. 
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3.3 STUDY PARTICIPANTS  
3.3.1 INTERVENTION GROUPS (II-IV) 
Criteria for inclusion in one of the intervention groups included age ≥18 years 
and indications for a unilateral or bilateral mastectomy, either for oncologic or 
prophylactic reasons, and IBR. The exclusion criterion was the inability to 
provide informed consent. Indications and operation techniques were 
discussed at an MDT conference in all cases. In cases were postoperative 
radiation was anticipated, late autologous reconstruction was recommended to 
the patient rather than IBR. 
The cohorts were operated on consecutively during different time intervals. 
From 2005 to 2014, patients were operated on with Surgisis ® (III and IV), 
and from 2015 to 2016, patients were operated on with TIGR® Matrix Surgical 
Mesh (II and IV). 
3.3.2 CONTROL GROUPS (III, IV) 
For the control group for study III, we recruited patients undergoing a 
technique involving muscle coverage and no mesh between 2005 and 2014. 
Inclusion and exclusion criteria were the same as those described for the 
intervention groups. For study IV, we compared two intervention groups that 
included patients operated on with synthetic (II) and biological (III) meshes. 
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3.4 INTERVENTIONS: SURGICAL METHODS 
3.4.1 MESH-ASSISTED RECONSTRUCTION (II–IV) 
Patients were marked preoperatively in a sitting position, with the anatomical 
boundaries of the breast, as well as those of the planned implant pocket and 
incision pattern, identified. In cases of a ptotic breast, a Wise pattern skin 
resection was performed; however, most cases received a sub mammary 
incision. In cases where previous surgery had been performed, modified skin 
patterns were used according to previous scars. A breast surgeon performed 
NSM or SSM accordingly.  
A plastic surgeon performed reconstruction. The inferior-lateral and -medial 
attachments on the sternum of the pectoralis muscle were released and the 
muscle was lifted in order to create a retro-pectoral pocket. The mesh was 
sutured to the inferior border of the pectoral muscle superiorly, to the chest 
inferiorly, and to the serratus fascia laterally using 2-0 Maxon® (Covidien, 
Dublin, Ireland) (Figure 9). A sizer was used to determine implant size, and an 
anatomical TE (CPX; Mentor Worldwide, LLC, Santa Barbara, CA, USA) or 
a permanent anatomical silicone implant (DTI; CPG; Mentor Worldwide, 
LLC) was placed into the pocket. When a TE was used, it was partially inflated 
with saline in order to achieve a tensionless closure.  
Two suction drains were used for each breast (one sub-pectoral and one 
subcutaneous), with the drains kept in place until the output was <30 mL/24 h. 
Prophylactic perioperative and postoperative antibiotics (cloxacillin; or 
clindamycin in case of allergy) were administered until drain removal. The 
amount of bleeding was estimated by the anaesthetist nurse in millilitres based 
on the amount of blood present in the compresses. The patients were admitted 
to the hospital for 48 h postoperatively, and TEs were exchanged for a 
permanent implant at 3 to 6 months after the first operation. 
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Figure 9. Schematic view of mesh insertion. (Niclas Löfgren) 
TIGR® Matrix Surgical Mesh (Novus Scientific, Uppsala, Sweden) was used 
in studies II and IV (Figure 10). This represents a synthetic, long-term, 
absorbable, macroporous mesh knitted from two types of fibres: a fast-
degrading copolymer between glycolide and trimethylene carbonate and a 
slow-degrading copolymer between lactic and trimethylene carbonate. The 
slow-degrading region of the mesh maintains its strength for 6 to 9 months and 
is completely resorbed after ~3 years, whereas the fast-degrading region 
provides additional strength during the healing phase and is gradually absorbed 
during the first 4-months post-surgery, thereby making the mesh softer and 
more flexible. Both regions of the mesh are degraded by hydrolysis into small 
molecules that are excreted from the body [98]. TIGR® Mesh has be used for 
multiple surgical techniques, including those involving hernia surgery [99] and 
for bra-implant-based breast reconstruction [100, 101].  
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Figure 10. TIGR® Mesh 
Surgisis® mesh (Cook, Inc., West Lafayette, IN, USA) was used in studies III 
and IV (Figure 11). This represents a sterile, biological, porcine-derived dried 
matrix comprising multi-layered, non-cross-linked collagen (types I, III, and 
V), gylcosamingylcans, proteoglycans, glycoproteins, and growth factors. This 
mesh is produced from small-intestine submucosa, is biodegradable, and works 
as an acellular scaffold that is subsequently incorporated and neovascularized 
in animal models and humans [102-106]. 
Figure 11. Surgisis® mesh. 
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3.4.2 TRADITIONAL MUSCLE-COVERAGE 
TECHNIQUE (III) 
In cases were the traditional muscle-coverage technique was used, the 
operation was performed as described, but a mesh was not used. When the 
major pectoral muscle was raised, the serratus muscle was raised accordingly 
and used to cover most of the upper and lateral aspects of the TE/I. 
 
3.5 STATISTICAL METHODS 
In study I, extracted data were pooled in meta-analyses, when possible, that 
were performed using Review Manager (RevMan v5.3; Copenhagen: The 
Nordic Cochrane Centre; The Cochrane Collaboration, 2014). We applied a 
random-effects model, with the effect estimate expressed as risk ratios (RRs) 
with 95% CIs. The individual studies and the pooled estimates were presented 
graphically using forest plots. Statistical heterogeneity was examined using the 
Chi-squared test and I-squared characteristics. 
In studies II through IV, categorical variables were represented as numbers and 
percentages, and continuous variables were represented as means and standard 
deviations, medians, and ranges. All tests were two-tailed, and a p < 0.05 was 
considered statistically significant. All analyses were performed with SAS 
software (v9.4; SAS, Cary, NC, USA). 
In study II, analyses were performed at the breast level and not at the patient 
level; therefore, generalized estimating equation models were used to predict 
minor and major complications during the entire study and within the first 30 
days. Calculations were adjusted according to within-individual correlations 
with a Poisson distribution and log-link function with robust error variances 
[107]. The analyses returned RRs with 95% CIs and p-values, and probability 
curves were generated in order to illustrate statistically significant predictors.  
In study III, differences between two groups were evaluated using Fisher’s 
exact test for dichotomous variables, the Chi-squared test for non-ordered 
categorical variables, and the Mann–Whitney U test for continuous variables. 
Relationships between two ordered categorical variables were tested using the 
Mantel–Haenszel Chi-squared test. Prediction of complications using baseline-
characteristic variables was performed using logistic regression, resulting in 
ORs and 95% CIs presented with their associated p-values. The area under the 
receiver operating characteristic curve (AUC) was used to generate 
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goodness-of-fit statistics and probability plots for graphical presentation. For 
continuous variables with an AUC >0.70, the cut-off maximising both 
sensitivity and specificity was identified, and a dichotomised variable based on 
this cut-off was analysed using logistic regression. All analyses were 
performed separately for permanent implants and TEs.  
In studies III and IV, HrQoL data were analysed in a similar manner, 
and scores from the questionnaires were calculated according to their 
respective manuals. For tests between two groups, Fisher’s exact test was 
used for dichotomous variables, and the Mann-Whitney U test was used for 
continuous variables. Relationships between two continuous variables were 
described and tested according to Spearman’s rank correlation. The adjusted 
analysis of tests between biological and synthetic mesh groups with respect 
to different Breast-Q domains was performed using logistic regression, with 
each group representing a dependent variable, and each domain at the time 
representing the main-effect variable. Variables were adjusted for age, BMI, 
unilateral/bilateral surgery, and radiation.  
 
3.6 ETHICS 
All procedures were performed in accordance with the Helsinki Declaration of 
1964, as revised, and Good Clinical Practice guidelines. Prior to 2017, 
permission to create a register of patients was obtained in accordance with the 
Swedish Privacy Protection Law. Since 2018, personal data have been treated 
in accordance with the General Data Protection Regulation. The studies were 
reviewed and approved by the Regional Ethical Committee (043-08).  
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4 RESULTS 
4.1 META-ANALYSIS OF BENEFITS AND RISKS 
WITH ADM AND MESHES (I) 
 
Fifty-one articles were included in the systematic review. The search and 
selection process is summarized in Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Overview of the process involved in determining the manuscripts 
included in Study I. Reprinted with permission from Taylor & Francis. 
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Overall complications were reported in 10 cohort studies and 18 case series. 
Pooled data from the 10 cohort studies showed an RR of 1.31 (CI: 0.94–1.81), 
but all studies reported severe limitations. The 18 case series reported overall 
complication rates ranging from 4% to 41%, with a low certainty of evidence 
(Grade II). 
Implant loss was reported in all of the included studies. Twenty-one case series 
and 16 cohort studies used in the analysis reported severe limitations, and 
meta-analysis of studies using ADM demonstrated a high heterogeneity, with 
an RR of 1.02 (CI: 0.65–1.58). Case series reported implant loss rates ranging 
from 0% to 17%, and it was uncertain whether there were small or no 
differences in implant loss rates between IBR with or without the use of a 
mesh. The certainty of evidence was very low (Grade I). 
Twenty case series and 21 cohort studies reported infections, although all of 
these studies also reported severe limitations. A meta-analysis showed an 
increased risk of infection when ADM was used [RR = 1.61 (CI: 1.20–2.15)], 
whereas meta-analysis concerning the use of a synthetic mesh showed no 
difference as compared with the use of no mesh. The included case series 
reported infection rates ranging from 0% to 17%. Due to study limitations, it 
was unclear whether the use of meshes increased the risk of infection. The 
certainty of evidence was very low (Grade I). 
Only five case series and five cohort studies reported results concerning 
capsular contracture, with all of these studies also reporting severe limitations. 
Three cohort studies reported on the use of ADM, and two reported on the use 
of synthetic mesh. The meta-analysis showed a relative RR of 0.55 (CI: 0.38–
1.69) comparing ADM versus no ADM, and the case series showed capsular 
contraction rates ranging from 0.4% to 13%. It was uncertain whether ADM 
versus no ADM decreased the risk of developing a capsular contraction in IBR. 
The certainty of evidence was very low (Grade I). 
Three studies reported aesthetic outcomes, with all of them using non-validated 
methods and reporting contradictory results. None of the studies reported 
patient-reported outcomes, and it was uncertain what the degree of differences 
was in aesthetic outcomes using ADM as compared with no ADM. The 
certainty of evidence was very low (Grade I). 
Håkan Hallberg 
43 
None of the studies reported complications specifically associated with 
radiotherapy in patients reconstructed with or without the use of meshes; 
therefore, a proper sub-analysis could not be performed. 
None of the studies reported HrQoL outcomes or recurrence of breast cancer. 
One study reported a delay in adjuvant therapy for 7 of 27 (26%) patients due 
to complications from breast reconstruction. The certainty of evidence was 
very low (Grade I). 
4.2 PARTICIPANTS AND CONTROLS IN STUDY 
II-IV 
Between 49 and 71 patients (65–132 reconstructions) were included in the 
different intervention groups, and 90 patients (132 reconstructions) were 
included in the control group (Table 5). The subjects were followed between 
17 and 162 months. 
Table 5. Overview of patients in studies II–IV. 
Study II, 
TIGR® 
Study III, 
Surgisis® 
Study III, 
Controls 
Study IV, 
Surgisis® 
Study IV, 
TIGR® 
Study type Case series  Cohort  Cohort 
No. of 
patients 
49 71 90 53 41 
No. of 
breasts 
65 116 132 n/a n/a 
Missing 
follow-up 
0 0 9* (see Table 8) (see Table 8) 
Surgical 
intervention 
TIGR® + 
permanent 
implant or 
expander 
Surgisis + 
permanent 
implant or 
expander 
Muscle-
covered 
permanent 
implant or 
expander 
Surgisis® + 
permanent 
implant or 
expander 
TIGR® + 
permanent 
implant or 
expander 
*Deceased from breast or ovarian cancer.
. 
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4.3 EARLY COMPLICATIONS (<30 DAYS) (II-IV) 
In study II evaluating the use of synthetic mesh (TIGR®), the overall 30-day 
complication rate (breast-level) was 23.1%, including four major 
complications (6.2%) and 11 minor complications (16.9%). Details are 
provided in Table 6. 
Table 6.  Early breast-level (studies II and III) and patient-level 
complications (study IV).   
* One patient had booth a pulmonary embolus and underwent reoperation 
due to a hematoma. 
**One patient in the Surgisis® group and three patients in the control group 
who were reconstructed bilaterally lost implants on both sides. 
  
Study II III/ Surgisis III/ Control IV/Surgisis
® 
IV/TIGR® 
    No. of 
Responders 
No. of 
Responders 
No. of breasts/ 
patients 
65/49 116/71 132/90 53 (53/71) 41 (41/49) 
Early 
complications 
(<30 days) 
     
Overall 15/65 
(23.1%) 
26/116 
(22.4%) 
27/132 
(20.4%) 
19 (35.8%) 12 29.3%) 
      
Major 
complications 
4(6.2%) 13/116 
(11.2%) 
15/132 
(11.3%) 
8(15.1%) 3(7.3%) 
Implant loss 2(3.1%) 13 (11.2%)** 15(11.3%)** 8(15.1%) 2(4.9%) 
Pulmonary 
embolism 
1(1.5%)* 0 0 0 1* (2.4%) 
Reoperation 
due to 
hematoma 
1(1.5%)* 0 0 0 * 
Minor 
complications 
11(16.9
%) 
14(12.1%) 12(9.1%) 11(20.7%) 8(19.5%) 
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In study III, the biological mesh group (Surgisis®) showed overall 
complication rates of 37% per patient and 22.4% per breast, both which were 
higher, but not statistically significantly, then rates in the muscle-covered 
control group [27% (per patient) and 20.4% (per breast); p = 0.24] (Table 6). 
The overall implant loss rate per breast was 11% in both the synthetic mesh 
group and the muscle-covered controls and 17% versus 13% at the patient 
level, respectively. There was a higher, but not significant, risk for any 
complication in the TE group operated on with Surgisis® as compared with 
that in the implant group (p = 0.056) (Figure 13). 
Figure 13. Complications in the biological mesh group and in muscle-covered 
controls. Complications are shown separately for implants and TEs.  
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4.4 LONG-TERM COMPLICATIONS/SURGICAL 
CORRECTIONS (II-IV) 
In study II evaluating the use of synthetic mesh (TIGR®), four minor surgical 
complications occurred and 10 minor aesthetic corrections were performed, 
with no implant losses occurring after day 30. There were two cases of capsular 
contraction (Baker II) not requiring surgical intervention during the follow-up 
period (Table 7). 
Table 7. Late breast-level (studies II and III) and patient-level (study IV) 
complications/surgical corrections.   
** Implant removal due to relapse 
*** Nine (9) patients diseased from breast or ovarian cancer. 
**** Baker grade II in two cases, not needing surgery. 
†One patient needed bilateral operation and is counted as one as this is 
evaluated as per-patient. 
Study II TIGR® III/ 
Surgisis 
III/ Control IV/Surgisis
® 
IV/TIGR® 
No. of 
Responders 
No. of 
Responders 
No. of 
breasts/patients 
65/49 116/71 132/90 53 (53/71) 41 (41/49) 
Late events (>30 
days) 
 21.5% 29.3% 26.5% 58.5% 19.5% 
Events needing 
surgery: 
10/65 
(15.3%) 
34/116 
(29.3%) 
31/117 
(26.5%) 
31/53 
(58.5)%) 
8/41(19.5%) 
Lipofilling (e.g., 
due to rippling) 
7/65(10.7%) 17/116 
(14.6%) 
15/117 
(12.8%)*** 
17(32.1%) 6(14.6%) 
Minor skin 
correction 
3/65(4.6%) 5/116 
(4.3%) 
4/117(3.4%) 5(9.4%) 2(4.9%) 
Capsular 
contracture 
2/65(3.1%) 
**** 
4/116 
(3.4%) 
2/117(1.7%) 3(5.6%)† **** 
Correction of 
implant position 
0 7/116 
(6.0%) 
8/117(6.8%) 6/53(11.3%) 0 
Other surgical 
intervention 
0 1/116 
(0.9%)** 
2/117(1.7%) n/a n/a 
Minor 
complications 
(no surgery) 
2/65(3.1%) n/a n/a n/a n/a 
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In study III, rates of capsular contraction during median follow-up was slightly 
higher in the biologic mesh group Surgisis®; 4.2% as compared with that in 
the control group, 2.5% per patient (3.4% vs. 1.7% per breast). Minor surgical 
corrections (mainly lipofilling) were performed in 29.3% of cases in the 
Surgisis® group and 26,5% of cases in the control group (Table 7). 
 
4.5 PREDICTORS OF COMPLICATIONS (II-III) 
In the synthetic mesh group (TIGR®) in study II, predictors for developing a 
complication within 30 days were age >51 years, BMI >24.5, and resection 
weight >361 g. There was also a 3-fold increased risk of complication when a 
Wise pattern incision was used (Figure 14). 
Predictors of developing any complication in the biological mesh group 
(Surgisis®) in study III were found to be BMI and radiation. Separate 
evaluation of DTI and TE in the implant subgroup revealed that the only 
statistically significant predictor of developing any complication was an 
elevated BMI. In the TE subgroup, the use of Surgisis® versus no Surgisis® 
was a predictor of complications, and radiation was a risk factor for implant 
loss, with the frequency of implant/TE loss higher in irradiated Surgisis® 
patients than in non-irradiated Surgisis® patients (40% vs. 11%, respectively) 
(Figure 14). 
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Figure 14. Predictors for complication in study II and III. 
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4.6 RESPONSES TO QUESTIONNAIRES 
 
In patients operated on with synthetic mesh (TIGR®), the first round of 
questionnaires was sent a median of 74 months (range: 43–162 months) after 
the operation, whereas in patients operated on with biologic mesh (Surgisis®), 
questionnaires were sent a median of 68 months (range: 43–158 months) after 
the operation. The controls received the questionnaires a median of 100 months 
(range: 44–162 months) after the operation. Response rates ranged from 68% 
to 84% across studies (Table 8). 
 
Table 8. Response rate to questionnaires in study III-IV 
 Study II, 
TIGR® 
Study III, 
Surgisis® 
Study III, 
Controls 
Study IV, 
Surgisis® 
Study IV, 
TIGR® 
Questionnaires — Breast-Q Breast-Q Breast-Q, 
HAD, 
EQ5D 
Breast-Q, 
HAD, 
EQ5D 
Responders — 49/71(69%) 55/81(68%) 53/71(75%) 41/49(84%) 
Non-
responders 
— 22/71(31%) 22/81(32%) 18/71(25%) 8/49(16%) 
 
 
In study IV, the overall per-patient complication rates were 35.8% versus 
29.3%, and the implant loss rate was 15.1% versus 4.9% in the Surgisis and 
TIGR groups, respectively (Table 6). Figure 15 shows information associated 
with responders versus non-responders. Of the patients answering the 
questionnaires in study IV, 58.5% in the Surgisis group underwent surgical 
corrections (lipofilling, skin corrections, and/or corrections due to capsular 
contracture) as compared with 19.5% in the TIGR® group (Table 7). 
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Figure 15. Responders vs. non-responders in study IV 
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4.7 PATIENT REPORTED OUTCOMES AND 
QUALITY OF LIFE (III, IV) 
 
Comparison of the biological mesh group with the synthetic mesh group (study 
III) revealed no statistically significant difference in ether of the domains 
according to Breast-Q (Figure 16). 
 
 
Figure 16. Breast-Q scores in the biological mesh group and the muscle covered 
controls. 
 
In study IV, the biological mesh group (Surgisis®) was compared with the 
synthetic mesh group (TIGR®), revealing no statistically significant difference 
between ether of the domains according to Breast-Q (Figure 17) or 
HAD/EQ5D (Figure 18) 
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Figure 17. Breast-q scores for the synthetic mesh group and the biological mesh 
group. 
 
Figure 18. EQ-5D and HAD-scores for the synthetic mesh group and the 
biological mesh group.  
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However, adjustment of the analysis for complications indicated that the 
biological mesh group with a higher complication rate (Table 7) scored 
significantly lower than the synthetic mesh group in terms of patient 
satisfaction with surgical outcome (p = 0.024). No statistically significant 
differences were found according to the other Breast-Q domains (Figure 19). 
Figure 19. Surgisis® - Relation between Breast-Q domains and complications 
and time from surgery to answered questionnaire. 
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5 DISCUSSION 
5.1 CONSIDERATIONS REGARDING THE 
RESULTS 
5.1.1 COMPLICATIONS INVOLVING MESH-BASED 
IBR 
There are a number of uncertainties that need to be considered when 
interpreting complication rates. These include the lack of consensus regarding 
how to define, diagnose, and report complications, and results reported as per 
breast or per patient also differ between reports. This makes comparison 
between different studies problematic. Additionally, variation in follow-up 
time is an important factor when complications are reported, as rates tend to 
increase along with time [45]. From this perspective, a common strength of the 
studies used in this analysis is that they involved longer follow-up periods 
(rang: 17–162 months). 
IMPLANT LOSS ACCORDING TO THE USE OF MESH  
The most significant breast-related complication in IBR is reconstructive 
failure or implant loss. Previous studies suggest that meshes/matrices might 
increase the risk of implant loss. Two reviews [108, 109] reported a 3- to 4-
fold increased risk of implant loss when using mesh as compared with 
traditional muscle-covered techniques. On the other hand, a recent randomized 
controlled multicenter study [110] comparing results obtained using porcine 
ADM (Strattice®; n = 64) with those from traditional muscle coverage (n = 
65) showed no difference in implant loss at a 6-month follow-up (6% in both
groups). Our results agreed with those findings, as we found an implant loss of
3.1% after a median follow-up of 23 months (range: 17–24) for patients
undergoing IBR involving a synthetic mesh (study II), with no difference in
implant loss between the biological mesh group and the traditional muscle-
covered groups (11% in both groups; study III).
Earlier reports on meshes/matrices[108, 109] reported higher incidences of 
implant loss as compared with more recent reports [110]. One explanation for 
this could be the learning curve associated with the use of meshes/matrices, as 
well as the necessity for technique development. The impact of surgeon 
experience on outcomes was previously addressed by Eriksson et al.[18] and 
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indicated that worse outcomes were reported in relation to surgeons with <5 
years of experience relative to those with >5 years of experience. Similarly, 
Barber et al.[111] reported that the implant loss rate ranged from 0% to 40% 
depending on surgeon experience. Although the difference was not statistically 
significant (p = 0.051), other indicators suggested that surgeon experience is a 
determinant of complication rates. In this thesis, we did not analyze the impact 
of surgeon experience; however, the implant loss rate of 11% in the earliest 
mesh cohort (study III; when meshes were first introduced in the clinic) as 
compared with 3% in the most recent mesh cohort (study II) might suggest the 
importance of experience. 
In summary, previous findings suggest that the implant loss rates presented 
here are considered acceptable and do not indicate an increased risk associated 
with the use of meshes. Additionally, the data indicated similar outcomes from 
the use of synthetic and biologic meshes, at least in short-term outcome. 
However, comparisons of implant loss rates between different studies are 
difficult due to the different confounders between different studies. 
OVERALL COMPLICATION RATES ACCORDING TO THE USE 
OF MESH 
The overall complication rates were consistent between early and more recent 
reports concerning the use of meshes/matrix[108-110]. Meta-analyses 
indicated an increased risk of complications when meshes/matrices are used as 
compared with when they are not used [RR = 2.8 (CI: 1.76–44.5) [108] and 
OR = 4.00 (CI: 2.33–6.88) [109]]. Additionally, Lomander et al. [110] reported 
a higher per-patient overall complication rate in the ADM group relative to that 
in the control group (41% vs. 29%, respectively), with a similar trend observed 
in in the present thesis. In study III, there was a higher overall per-patient 
complication rate in the mesh group (Surgisis®) relative to that in the control 
group (37% vs. 27%; p = 0.0056); however, when comparison of per-breast 
complication rates revealed similar rates between groups (22.4% vs. 20.4%, 
respectively). In study II, the overall early complication rates were in line with 
those in study III (23.1%) but with a somewhat lower risk of major 
complications (6.2%; 3.1% of which were breast related). 
The overall complication rate reported in different studies ranged from low to 
high. This might be explained by that variation in how each study defined and 
reported complications. For example, the rates would different significantly 
depending on their being reported per breast or per patient, as shown in this 
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thesis. The two breasts of a given patient cannot be considered independent of 
each other according to the risk profile of that patient for certain complications. 
Therefore, inadequate notification of how the rates were reported can result in 
a flawed interpretation of the results.  
In summary, the overall complication rates presented in this thesis are in 
agreement with previously reported findings[110] and were similar in 
operations with and without the use of mesh. 
 
COMPLICATIONS ASSOCIATED WITH THE USE OF 
SYNTHETIC OR BIOLOGICAL MESHES 
There are few comparisons of complication rates between the use of biological 
or synthetic meshes in the literature. In a prospective, randomized trial by 
Gschwantler et al.[41], they found no significant difference in overall 
complication rates between biological (Protexa) and synthetic (TiLoop) 
groups; however, the risk of a severe complication leading to reconstructive 
failure was initially reported as highly significant in the biological mesh group 
(30% vs. 8%; p < 0.0001), although this was later corrected to a non-significant 
difference[42]. That study was later criticized for its study design [43]. 
Similarly, the analysis performed in this thesis suggested that use of a synthetic 
mesh might result in less serious complications relative to use of a biologic 
mesh (studies II and III). Meta-analysis of study I revealed that the risk of 
infection was statistically higher in the biological mesh group than in the 
synthetic mesh group [RR = 1.61 (CI: 1.20–2.15)]; however, these results 
should be interpreted with caution due to the low quality of included studies. 
Overall, the data suggest a possibly higher risk of serious complications in 
reconstructions using biological rather than synthetic meshes. 
 
LONG-TERM COMPLICATIONS ACCORDING TO THE USE OF 
MESH 
A Swedish national survey [17] reported that 52% of patients that had 
undergone IBR experienced at least one postoperative complication, with 64% 
resulting in re-operation (median follow-up: 6.6 years). However, that study 
did not report whether meshes were used. Clarke-Pearson et al. [112] compared 
IBR with DTI and ADM with TE/I without a mesh and reported a revision rate 
of 20% in both groups.  
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The long-term revision rates reported in this thesis (studies II and III) were 
15.3% in the TIGR® group and 29.3% and 26.5% in Surgisis® and control 
groups respectively, with most of the surgical corrections qualifying as minor 
procedures (e.g., lipofilling, implant position correction and surplus skin).  
 
CAPSULAR CONTRACTURE ACCORDING TO THE USE OF 
MESH 
Previous studies suggested that the use of biological ADM might prevent 
capsular contracture [113-115]. However, we were unable to confirm this 
according to the studies analyzed, as the frequency of capsular contracture 
was higher in the mesh group than in muscle-covered controls (study III). In 
study I, the meta-analysis showed no significant difference in the incidence 
of capsular contraction with or without biologic meshes [RR = 0.55 (CI: 
0.38–1.69)]. 
There are no studies reporting the effect of synthetic meshes on the occurrence 
of capsular contracture; however, in the cohort analyzed for this thesis, this 
incidence was very low (study II). Generally, incidences of capsular 
contracture increase over time, with Salzberg et al reporting that capsular 
contractions can occur up to 2-years postoperatively according to a cohort 
followed for 13 years [114]. The follow-up in study II was only 17 months in 
some cases, suggesting that longer-follow up periods are needed to investigate 
the effect of synthetic meshes on the formation of capsular contracture.  
 
FACTORS AFFECTING COMPLICATIONS  
Irradiation  
Previous studies show that both preoperative and postoperative irradiation 
increases the risk of complications associated with IBR [69, 71, 111]. A 
multivariate analysis  by Eriksson et al. [18] indicated that preoperative 
radiotherapy had an HR of 9.28 (p < 0.01), and postoperative radiation had an 
HR of 3.08 (p < 0.01) associated with the risk of reconstructive failure. 
Similarly, Spear[116] reported that irradiation increased the complication risk 
11 fold for IBR involving human ADM (Alloderm). 
Our findings showing a 3-fold increased risk [OR = 3.10 (CI:1.07-8.92; p = 
0.036)] for complications in the Surgisis® TE/I group receiving radiation 
(study III) agreed with those of previous studies. Moreover, we found that the 
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complication frequency was considerably higher in patients reconstructed with 
TIGR® and having a history of irradiation (study II). Notably, irradiation has 
a long-term effect on tissue, with subsequent effects on implants possibly 
manifesting at a later time; therefore, the negative effect of irradiation might 
be underestimated in the included studies [18]. It remains unclear what role the 
mesh/matrix might have on complication rates associated with 
irradiation[117]. A review by Clemens et al. [117] concluded that ´use of ADM 
for implant-based breast reconstruction does not appear to increase or 
decrease the risk of complications´, with this suggesting that in the context of 
irradiation, the presence or absence of mesh might be of little importance 
concerning the complication rate.  
DTI versus TE/I 
A proposed advantage of meshes/matrices is that IBR can be performed as a 
DTI reconstruction, thereby avoiding the use of TEs and staged reconstruction 
[34]. The risk of complications associated with DTI versus TE/I varies in the 
literature. Srinivasa et al. [28] reported  higher complication rates in the DTI 
group; however, after adjusting for baseline characteristics, an equal risk of 
complications between the two groups was found. By contrast, a review by 
Basta et al. [27] concluded that there was a higher risk for both flap necrosis 
and implant loss when a DTI was performed. In a randomized controlled trial 
by Dikmans et al. [118]one-stage IBR with ADM was associated with 
significantly higher risk per breast of surgical complications. Major adverse 
events occurred in 29% in the one-stage IBR with ADM group and in five (5%) 
in the two-stage IBR group. The risk for implant loss was higher in the one-
stage IBR group, with an OR at 8.80(CI:8.24–9.40; p<0·001). 
Regarding the use of meshes/matrix in one- and two-stage reconstruction, 
respectively, Azouz et al. [119] found that use of human ADM (Alloderm 
RTU) increased the complication frequency associated with a staged 
reconstruction with a TE (40.5% vs. 28.2%; p = 0.037). A similar result was 
observed in study III, where the complication frequency was higher in the TE 
group than in the implant group (p = 0.0056). However, it remains unclear 
whether the risk is greater when meshes and matrices are used in connection 
with TEs.  
In summary, there are conflicting results in current literature comparing 
outcomes in IBR involving DTI versus TE/I. In one randomized trial[118] in 
this area, there was a significant increased risk in the DTI group, but the choice 
of whether to perform DTI or  TE/I is often made based on patient 
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characteristics and local traditions at the clinic. This introduction of bias into 
the process of selecting a surgical method could be one explanation for the 
divergent results. 
Study III included more patients operated on with TE/I. One reason is that at 
the time of this study, the policy at the clinic was not to perform NSM. 
Moreover, in many cases, the remaining skin envelope was not sufficient for a 
DTI reconstruction, thereby resulting in a TE/I reconstruction being chosen. 
Another explanation might be that Surgisis® material is thin relative to that of 
dermis-derived meshes; therefore, it is plausible that Surgisis® material is 
mechanistically inadequate for forming contacts with the overlapping flap in a 
manner similar to a stiffer mesh, resulting in its early degradation prior to initial 
integration.  
 
Patient-related factors  
Patient-related factors play a role in the risk of complications. Several studies 
report that BMI [18, 63, 65, 112], smoking status [63, 64, 112], the amount of 
resected breast tissue [65, 120], and age [63, 66] are  risk factors for 
complications associated with IBR. Similar findings were reported in the 
present analysis, with smoking being an exclusion criterion for breast 
reconstruction in Sweden and, therefore, not investigated. it was not 
determined whether patient-related factors have a synergistic effect along with 
the use of meshes/matrixes concerning the risk of complications. 
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5.1.2 PATIENT SATISFACTION WITH MESH-BASED 
IBR 
POPULATION NORMS 
Surgeries were performed in a similar manor, except for the use of ADM/mesh 
versus no ADM/mesh in studies II, III and IV. However, the results in those 
studies might have been affected by factors other than the surgical technique 
used.  
Unfortunately, normative values for Breast-Q in a Swedish population are 
missing; thereby precluding comparison. Mundy et al. reported normative 
values for an American population of 1201 women [121]; therefore, we used 
this data and Breast-Q scores from two other studies [122, 123] for comparison 
with our results from studies III and IV (Figure 20). 
 
 
 
 
 
 
 
 
 
Figure 20. Comparison of results with Breast-Q normative data.  
Kouwenberg [93] used EQ-5D to assess outcomes from IBR, irrespective of 
surgical technique (n = 103), finding a mean EQ-5D score of 0.851 ± 0.17. 
Additionally, Fernandez-Delgado [95] reported scores for HADS-anxiety 
(3.99) and HADS-depression (2.90) following analysis of 153 patients 
undergoing IBR. Comparison of these results with our data (Figure 21) 
indicated that our findings agreed with previous results associated with 
measurement using EQ-5D, HADS, and its subdomains. 
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Figure 21. Comparison of results with HADS/EQ-5D normative data 
We observed no significant differences in the reported Breast-Q scores 
between groups in studies III and IV, except for those reporting a complication 
and resulting in a significantly lower score involving satisfaction with 
outcome. A previous study reported a similar finding from patients 
experiencing complications [18]. Our results were comparable in most Breast-
Q, EQ-5D, and HADS domains, indicating small differences between 
reconstructed populations and those not undergoing reconstruction.  
These findings suggest no differences in the outcome regarding the timing of 
implant-based reconstruction or the use of ADM/meshes. However, it is also 
possible that the instruments used to detect differences in such outcomes are 
currently inadequate.  
EQ-5D VAS HADS - anxiety HADS - depression
Comparison of outcome in EQ-5D and HADS 
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5.2 METHODOLOGICAL ISSUES: STRENGTHS 
AND LIMITATIONS 
5.2.1 METHODOLOGICAL ISSUES REGARDING 
SYSTEMATIC REVIEW AND META-ANALYSIS 
(I) 
The strengths of a systematic review and/or a meta-analysis are that these 
techniques offer a more objective appraisal of the evidence and increased 
statistical power, as they summarize the results of all available studies [124]. 
The validity of these techniques is dependent upon the scientific quality of the 
different steps of the review process. To minimize the risk of bias, we 
employed a rigorous protocol and the PRISMA statement guidelines [125] in 
this thesis. Additionally, to ensure adequate quality in every step, a high 
competence level in the individuals involved in each step (e.g., professional 
librarians, breast surgeons, plastic surgeons, and experts in meta-analysis 
statistics) was confirmed. 
Nevertheless, the quality of such an analysis is susceptible to the quality of the 
included studies. Despite the use of rigorous eligibility criteria, the 
methodological quality of the available studies was generally low, with these 
studies often including small sample sizes and suboptimal research designs. 
Additionally, many involved a risk of reporting bias, as well as unclear 
inclusion and exclusion criteria, the complications included, and how they 
were diagnosed. Moreover, many studies failed to separately report data for 
irradiated and non-irradiated patients. As a result, some of the reported 
outcomes and the estimated size effect might be questionable; therefore, the 
results of our assessment of study heterogeneity could represent characteristics 
associated with these potential shortcomings.  
Meta-analysis results are also susceptible to the statistical methods used to 
analyze the data. A statistical shortcoming in this thesis was that most of the 
studies reported a number of patients, breasts, and complications but not how 
many patients experienced bilateral complications. Moreover, patient 
characteristics were frequently unspecified; therefore, the meta-analysis had to 
be performed based on complication per breast (aggregate data) rather than 
complications per individual (individual participant data).  
Briefly, a meta-analysis is highly dependent on the quality of the included 
studies. With the rigorous methodology applied in study I, the results should 
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reflect the best evidence currently available; however, the quality of the 
evidence was low. 
 
5.2.2 CONSIDERATIONS REGARDING THE 
MEASUREMENT OF QOL (III, IV) 
Since the 1990s [126], HrQoL has become an increasingly important outcome 
measurement in many fields, including cancer treatment and reconstructive 
surgery. This measurement encompasses not only the length of survival and 
frequency of complications but also the impact on patient QOL and perspective 
[126, 127]. Evaluating HrQoL requires consideration of a number of factors, 
some of which are discussed in this section. 
Minimal important difference (MID)  
The MID is the smallest difference in an HrQoL score and that patients 
perceive as beneficial. The value is often related to 50% of the baseline 
standard deviation in subscale scores and in an effect size of 0.5, although there 
is no consensus on how MID should be determined [128]. Moreover, there are 
no MID-related data for Breast-Q reconstruction; however, a study on the 
augmentation module in Breast-Q [128] demonstrated that the mean MIDs for 
the different subscales of that particular module include the following: 
satisfaction with breasts, 8 (range: 7–8); psychosocial well-being, 10 (range: 
8–11); sexual well-being, 10 (range: 9–10); and physical well-being, 7 (range: 
2–11). For the HADS, MIDs only exist for patients that have survived 
respiratory failure [129]. For that group, the MID was ~2.5 for both the anxiety 
and the depression modules. For the EQ-5D-3L, the MID for patients that 
underwent glioma surgery ranged from 0.13 to 0.15 [130]; however, these 
MIDs might not be relevant in the setting of breast reconstruction (our patient 
sample), but could give an indication of what range of differences are needed 
to detect a clinically significant difference. The differences between the 
Surgisis® and muscle-covered implant groups (study III) and the synthetic and 
biological mesh groups (study IV) were much smaller than the previously 
published MIDs (Figure 16, 17, 18). 
In clinical research, a p < 0.05 is often used to indicate a statistical difference 
and to dichotomize between the presence or absence of a “treatment effect”; 
however, a p-value indicates a statistical probability and does not necessarily 
imply a clinically significant difference [131]. In this thesis, statistical tests 
were used to compare clinical differences in complication rates (studies II and 
III) and HrQoL (studies III and IV), with no differences detected between the 
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groups (Figure 16, 17, 18 and Table 6, 7). The statistical tests together with the 
small differences in absolute scores (likely smaller than the MIDs) might 
indicate that there were truly no differences in HrQoL between the groups.  
Response shift 
Schwartz and Sprangers[132] defined response shift as “a change in the 
meaning of one’s self-evaluation of a target construct as a result of: (a) a 
change in the respondent’s internal standards of measurement (i.e., scale 
recalibration); (b) a change in the respondent’s values (i.e., the importance of 
component domains constituting the target construct); or (c) a redefinition of 
the target construct (i.e., reconceptualization)”. A more easily understandable 
definition of response shift was proposed by Rapkin et al. [133]. “QOL 
response shift may best be understood as an epiphenomenon: individuals' 
ratings of QOL can respond to changes in illness, treatment, and other life 
events in atypical (e.g., statistically different from some expected value) ways 
or in ways that do not gibe with external observation. Changes in QOL 
appraisal may be able to account for these discrepancies”[133]. 
HrQoL scores can be incorrectly interpreted if response shift is not taken into 
account [134]. This is particularly relevant when evaluating a mixture of 
therapeutic and prophylactic mastectomies. A response shift was reported early 
after diagnosis among breast cancer patients [135], and HrQoL in disease-free 
breast cancer patients 5 years after treatment were comparable to that in healthy 
women [136]. On the other hand, response shift has never been studied in 
patients undergoing prophylactic mastectomy and reconstruction. 
In summary, response shift would have been used if we had included baseline 
values in the different populations; however, given that a long period of time 
had elapsed since surgery in our cohorts, response shift likely would have had 
a minimal effect on the HrQoL results, but might have hide treatment 
effects[135].   
Regression to the mean 
The questionnaire results are interpreted at the group level; therefore, it is 
unclear whether subgroups in the cohorts benefitted more or less from the 
treatment. Additionally, a previous study noted that patients can adapt to a 
given state before a change in life (regression to the mean [137]), which can 
make interpretation of results difficult. One example is that a group of breast 
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cancer patients followed for 5 years adapted to their status over time, with their 
response comparable in many aspects to those from the general population 
[136].  
 
Missing data and attrition bias  
Missing data can affect the result of questionnaire responses, as there might be 
systematic differences between patients answering the questions and those who 
do not, thereby potentially introducing selection bias. A higher frequency of 
missing data increases the risk of bias in result interpretation, and a previous 
study suggested that a loss of <5% of responses would likely result in minimal 
bias, whereas a loss of >20% could potentially harm the validity of the results 
[138]. 
In study III, the questionnaire response rates were 69% and 68% for the 
Surgisis® and control groups, respectively, whereas the study IV response 
rates were 76% and 84%; biological and synthetic mesh groups, respectively). 
In study IV, all responders answered the Breast-Q questionnaire in both 
groups; however, in the biological mesh (Surgisis®) group, 14/53 and 17/53 
questionnaires were incomplete for EQ-5D and HADS, respectively. In this 
group, nine patients had died at follow-up (Table 6); therefore, this exceeded 
the 20% threshold and potentially threatened the validity of the results. 
However, all of the patients that had experienced complications answered the 
questionnaires, suggesting that the questionnaires were not answered only by 
those patients satisfied with their outcome (study IV). Nevertheless, it is 
possible that the missing data could have introduced bias that affected the 
comparison between groups (studies III and IV).  
 
Relevance of the HrQoL instruments used 
The main objective of using HrQoL instruments as an outcome measurement 
in clinical studies is to collect evidence related to the results from the patient’s 
perspective. To ensure accuracy, such instruments need to be scientifically 
validated and tested for reliability. A previous study [139] recommended 
minimum standards for patient-reported outcome measurements according to 
patient-centered outcomes. Additionally, the instrument needs to be relevant 
to the research question posed. The instruments used in this thesis meet the 
recommended requirements for HrQoL instruments in regard to their validity, 
reliability, interpretability. 
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To ensure that the instruments were relevant to the research question, this 
thesis employed one disease-specific instrument, designed especially to 
capture patient perspective on breast reconstruction, and two generic 
instruments, previously used in different populations. It is difficult to use 
generic instruments to evaluate a specific treatment modality, and there is often 
no evidence confirming their validity for use to evaluate breast reconstruction 
(i.e., they are responsive and sensitive to changes after surgery [140]). 
Nevertheless, generic instruments remain the most used instruments in 
reconstructive surgery, and a combination of generic and specific instruments 
is likely the optimal way to evaluate HrQoL following breast reconstruction 
[140]. Therefore, we believe that the use of a combination of generic and 
disease-specific instruments in this thesis was relevant to the research 
questions being addressed. 
Data analysis 
There is no consensus on how HrQoL should be statistically analyzed, which 
makes comparison between different studies difficult [141]. In this thesis, a 
clear research hypothesis was formulated when HrQoL was included, and only 
domains of interest were included in the analysis. This limed the number of 
statistical analyses and potentially reduced the risk for a type 1 error. 
Moreover, we adjusted for variables, such as age, BMI, unilateral/bilateral 
surgery, and radiation treatment, potentially affecting the surgical outcome 
(study IV). One limitation was that missing data were not handled in the 
statistical models.  
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5.2.3 CONSIDERATIONS REGARDING STUDY 
DESIGN, SAMPLING, POWER, AND 
REPRESENTATIVENESS  
Meshes and matrices have been used in clinical practice since 2005 and are 
currently used in the majority of implant-based breast reconstructions in the 
United States [34]. Therefore, studies II through IV allowed comparisons of 
surgical effectiveness research, as they focused on evaluating clinical 
treatments currently used on the general population [142].   
In these studies, outcome measurements were based principally on the patients 
and providers being considered as stakeholders, suggesting that the goal was 
to identify the best available treatment for the patients in order to improve the 
quality of care, proficiency, and information received by the patients [143]. 
One strength of the studies was that they were originally designed to monitor 
the quality of mesh and matrix use in our clinic. Therefore, prospective 
collection of the clinical data was standardized, enabling the data to be 
aggregated, and IBR methods to be compared over a period of 13 years. 
Additionally, the drop-out rate was low, allowing data to potentially be 
retrieved during long-term follow-up from almost the entire cohorts for both 
studies II and III.  
Another strength of these studies involved the long follow-up time, which is 
particularly important when complications are reported. A previous study [45] 
reported low complication rates of 5.9% at day 30, whereas the rate increased 
to 18.9% at 1 year. In the studies analyzed for this thesis, patients were 
followed for a minimum of 17 months and up to 162 months.  
Methodological weaknesses associated with data collection from a clinical 
setting include variations in how clinical practices represent certain data, 
including surgeon learning curves when different meshes are used, small 
variations in surgical technique, and patient selection. However, relatively few 
surgeons have performed immediate reconstructions over the 13-year period 
of the included studies, during which time senior surgeons have consistently 
trained new surgeons joining the team. We believe that the effect of variations 
in clinical practice is likely minimal in the present cohorts, although variations 
in clinical practice might have introduced bias into the interpretations of the 
results. Furthermore, the evaluation of specific clinical practices might have 
diminished the risk of performance bias possibly existing had the patients been 
randomized according to the use of different meshes. Unfortunately, surgeons 
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cannot be blinded to what mesh they use; therefore, employment of a 
randomization process would have likely been nullified by the personal 
preference of the surgeon.  
In clinical research, the ideal study design for comparing treatment effects 
involves sampling by randomization; however, the study design used for this 
thesis precluded randomization. In studies II through IV, a consecutive 
sampling technique was used, where all consecutive patients fulfilling the 
inclusion criteria were included in a certain cohort. Additionally, the surgical 
methods used were determined according to the current clinical practice used 
by the department. Nevertheless, employment of a random-sampling technique 
might have strengthened our studies. 
A clear weakness of consecutive sampling is that the sample size became 
arbitrary, which might have underpowered the studies, with the small sample 
sizes potentially precluding the option of rejecting the null hypothesis [144]. 
Therefore, it is possible that the lack of differences observed between the use 
of Surgisis® and muscle-covered implants in study III and between synthetic 
and biological meshes in study IV could be explained by the sample sizes being 
too small to allow the detection of differences. Nevertheless, the small 
differences in the real scores calculated between the groups (Figure 16, 17, 18) 
might suggest that the lack of differences observed between the groups was not 
a result of a type II error.  
Another weakness of small cohorts is that they might not be representative of 
the overall population needing IBR, and that minor differences in the cohorts 
might cause bias. In this thesis, this might be relevant in the comparison of the 
cohorts between studies III and IV; however, there were no differences in 
demographic factors or the reasons for surgery between the cohorts, except for 
there being more bilateral cases in the biological mesh cohort as compared with 
the synthetic mesh cohort in study IV. Therefore, these characteristics suggest 
that that the cohorts might be representative of the population needing IBR, 
regardless of sample size. 
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6 CONCLUSIONS 
This thesis investigated the different aspects of mesh- and ADM-assisted IBR, 
with the main conclusions as follows: 
 Meta-analysis revealed the possibility of an increased risk
of infections associated with the use of ADM but not
when synthetic meshes are used. This result should be
interpreted with caution due to severe limitations with the
majority of the included studies.
 IBR combined with a synthetic mesh (TIGR®) can be
performed with expectations of a relatively low risk of
short-term complications. Although later complications
mostly involved issues requiring minor corrections for
aesthetic reasons, a longer follow-up period is needed to
establish risks of capsular contracture associated with
synthetic meshes.
 The overall complication rate was higher when a
biological mesh (Surgisis®) was used as compared with
muscle-covered implants, although no significant
difference was noted in implant loss rates between the
groups. Predictors of complication were mainly patient
related. Notably, a high complication rate associated with
TE reconstruction was found, especially in patients with
a history of irradiation.
 Long-term patient satisfaction and QOL were similar
between those undergoing IBR involving Surgisis® or
muscle-covered implants.
 There were few differences in reported QOL between
patients undergoing IBR involving a synthetic or biologic
mesh, with the occurrence of complications being a
determining factor of patient satisfaction with the surgical
outcome. This might suggest that the use of biological or
synthetic meshes provides similar long-term QOL.
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7 FUTURE PERSPECTIVES 
The benefits of using meshes and matrices in IBR remain unclear, although 
this thesis concluded that the risks associated with their use seem to be 
comparable with traditional muscle covered reconstructions. However, this 
does not imply that they ensure superior outcomes relative to traditional 
muscle-covered techniques. Long-term benefits concerning capsular 
contracture rates and patient QOL could not be verified in this thesis. 
Moreover, it remains unclear whether biological meshes are superior to 
synthetic meshes in any aspect. 
Any benefits of a given technique need to be analyzed relative to the costs. 
Biological meshes add a considerable material cost to IBR, whereas synthetic 
meshes are considerably more cost-effective. To clarify the beneficial or 
detrimental role of meshes and matrices in IBR, long-term health-specific 
economic studies and analyses involving comparisons with other 
reconstructive options are necessary.  
Randomized controlled trials are necessary to further elucidate whether 
biological and synthetic meshes provide different outcomes. Meshes have only 
been used since 2005; therefore, the current extent of long-term follow-up is 
capped at ≤14 years, thereby limiting the ability to critically assess long-term 
outcomes.  
Because relatively few studies of high scientific quality have been conducted 
on the use of meshes, studies concerning patient selection, surgical techniques, 
and the choice of implant type remain important in order to ensure appropriate 
application of meshes in breast reconstruction. 
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